褪黑素对大鼠肝纤维化的保护作用及其对NF-κB活性的影响
|
摘要
背景/目的
肝纤维化是慢性肝病共有的病理特征,其过程涉及到多细胞、多分子事件,最终导致胶原和细胞外基质(extracellular matrix, ECM).在狄氏间隙沉积,并能发展为不可逆性肝硬化。近年来的研究证实,肝纤维化在未进入肝硬化之前,尚有逆转可能。在此阶段,如果处理得当,肝硬化有可能避免。然而,目前尚无理想的治疗肝纤维化药物。因此,探讨肝纤维化的机理,开发有效和毒副作用小的治疗肝纤维化的新药是目前研究的重要方向。目前有证据提示,氧化应激在肝纤维化的发生和发展中起重要作用。
褪黑素(N-acetyl-5-metyoxytryptamine, melatonin)是松果体分泌的一种激素,为强大的内源性抗氧化剂,能清除氧自由基和中间活性体。体内和体外实验显示,在由黄樟素、脂多糖(LPS)、四氯化碳(CCl4)、缺血再灌注、淀粉状蛋白质、电离辐射等诱导的氧化损伤中,褪黑素具有保护细胞、组织和器官的作用。另外,褪黑素还通过提高谷胱甘肽过氧化物酶(GPx)、超氧化物歧化酶(SOD)、谷胱甘肽(GSH)这些潜在性的抗氧化剂的水平而间接发挥抗氧化作用。近年研究显示,褪黑素具有减少纤维母细胞增殖、抑制胶原合成作用。但褪黑素对肝纤维化的保护作用研究尚少。
核转录因子кB(Nuclear factor-kappaB ,NF-кB)是由二聚体构成的转录因子家族,具有调控炎症、免疫、创伤愈合、细胞生存、细胞功能等作用。生理应激、氧化应激、暴露于某些化学品均可导致NF-кB激活,进而发挥其关键性的应激反应调节作用。NF-кB过度激活与许多疾病有关。近来NF-кB在肝脏疾病中的功能和调控受到关注,肝脏的损伤和纤维增生涉及到NF-кB的活化。NF-кB在肝纤维化中的确切作用尚不甚清楚,褪黑素对纤维化肝脏中NF-кB活性的影响及其后果未见系统研究。本课题在建立大鼠CCl4诱导的化学性肝纤维化模型基础上,探讨MEL对肝纤维化的抑制作用和可能机制。同时,探讨NF-кB在CCl4诱导的化学性肝纤维化中的作用,以及MEL是否通过抑制NF-кB活性而发挥抗纤维化作用。
方法
采用四氯化碳(carbon tetrachloride ,CCl4)制备SD大鼠化学性肝纤维化模型。所有大鼠随机分为6组:正常对照组(normal control group,normal组,11只)、模型对照组(model control group, model组,20只)、CCl4+N-乙酰-L-半胱氨酸组(NAC组,为阳性药对照,20只)、CCl4+低剂量褪黑素组(MEL1组,20只)、CCl4+中剂量褪黑素组(MEL2组,20只)、CCl4+高剂量褪黑素组(MEL3组,20只)。将CCl4与精制花生油按2 :3比例配成40%CCl4油剂溶液,除正常对照组外,余按3ml/kg给大鼠皮下注射,每周两次,连续12周,正常对照组注射等容量花生油作为对照。自动物皮下注射CCl4之日起,开始给药, NAC 100 mg/kg, i.p.,每天1次;MEL低、中、高剂量组分别给予MEL 2.5 mg/kg、5 mg/kg、10 mg/kg,均为腹腔注射。12周实验结束后,所有动物予以麻醉,腹主动脉取血,取出肝脏并称湿重。HE染色和Van Gieson (VG)胶原纤维染色观察肝脏病理改变;全自动生化分析仪检测血清谷丙转氨酶(alanine aminotransferase, ALT)、谷草转氨酶(aspartate aminotransferase ,AST)、白蛋白(albumin, A)、球蛋白(globulin, G )水平;生化法测定肝脏羟脯氨酸(hydroxyproline ,Hyp)、丙二醛(malondialdehyde ,MDA)含量和谷胱甘肽过氧化物酶活性(glutathione peroxidase ,GPx);放射免疫法测定血清透明质酸(hyaluronic acid,HA)、层粘连蛋白(laminin,LN)、三型前胶原氨端肽(procollagenⅢN-terminal peptide,PⅢN P)含量;免疫组化法测定肝组织中NF-кB P50、NF-кB P65、肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)、细胞间粘附分子-1(Intercellular adhesion molecule-1,ICAM-1)的表达;RT-PCR法测定肝组织中Ⅰ型前胶原(procollagen typeⅠ)mRNA表达;电泳迁移率改变分析(electrophoretic mobility shift assay ,EMSA)测定肝组织中NF-кB DNA结合活性;同时,用原位灌注加密度梯度离心法分离正常SD大鼠肝脏星状细胞,以免疫组化法鉴定(用desmin抗体),在培养的肝星状细胞中加入脂多糖(LPS)进行刺激,用MTT法测定不同浓度的MEL对肝星状细胞增殖的抑制作用。
结果
1. MEL对大鼠化学性肝纤维化的保护作用
通过12周皮下注射CCl4,成功建立了大鼠肝纤维化模型。病理分级显示:正常对照组和CCl4处理各组之间差异显著(P < 0.01),和模型组相比,MEL(10 mg/kg)组肝纤维化程度较轻,有统计学意义(P < 0.05),表明MEL(10 mg/kg)有抑制肝纤维化作用。与正常对照组比较,CCl4处理各组血清ALT、AST水平显著升高(P < 0.01),与模型组比较,MEL(5, 10 mg/kg)能显著降低升高的的ALT、AST水平(P < 0.05,P < 0.01),NAC也能显著降低升高的ALT、AST水平(P < 0.05),其作用强度和MEL相近。同样,与模型组比较,MEL(10 mg/kg)能降低肝脏Hyp含量和LN、HA水平,表明MEL对纤维化标志物的改善。另外,MEL对氧化应激指标也有明显影响,和模型组比较,MEL(5, 10 mg/kg)能显著降低肝匀浆MDA含量(P < 0.05),升高GPx活性(P < 0.05,P < 0.01),NAC也有同样作用,其作用强度和MEL(10 mg/kg)相近。
2. MEL对LPS介导的肝星状细胞增殖的影响
通过原位灌注和密度梯度离心法成功分离并纯化大鼠肝星状细胞,刚分离的星状细胞纯化至70-80%,存活率在90 %以上,纯化的星状细胞得率2×107/肝。传第一代的细胞,S-P法作免疫细胞化学鉴定,Desmin表达阳性细胞为90%以上。与对照组(无LPS刺激)相比,培养的肝星状细胞经LPS(10ng/ml)刺激后,增殖明显加快,与LPS组相比, MEL(0.1mmol/L)能显著抑制由LPS刺激的肝星状细胞增殖。
3. MEL对纤维化大鼠肝组织I型前胶原mRNA表达的影响
正常对照组大鼠肝组织I型前胶原mRNA表达较少,和CCl4处理各组相比,差异显著(P<0.05,P<0.01)。和模型组相比,MEL(10 mg/kg)组、NAC组表达明显减少(P<0.05),MEL(2.5 mg/kg, 5 mg/kg)表达有下降趋势,但无统计学意义。这些结果表明MEL有抑制肝脏纤维化大鼠I型前胶原mRNA表达作用。
4. NF-кB在CCl4诱导的大鼠肝纤维化中的作用以及MEL对NF-кB信号通路的影响
NF-кB P65、NF-кB P50在正常对照组大鼠肝组织中仅有微量表达,表现为细胞浆中淡黄色颗粒,较之正常对照组,CCl4处理各组表达明显增强,表现为棕黄色和/或棕褐色颗粒,且细胞浆和细胞核中均有表达,和模型组相比,MEL(5, 10 mg/kg)、NAC均能显著降低NF-кB P65、NF-кB P50的表达。进一步, NF-кB DNA结合活性被测定,结果显示,正常对照组NF-кB结合活性较弱,模型组NF-кB结合活性较其它各组明显增强,和模型组相比,MEL能明显抑制NF-кB的结合活性。
TNF-α、ICAM-1在正常对照组大鼠肝组织中仅很微量表达,表现为细胞浆中淡黄色颗粒,较之正常对照组,CCl4处理各组表达明显增强,表现为棕黄色和/或棕褐色颗粒,以血管周围,汇管区炎性细胞较多的区域最为明显,其表达强度弱于NF-кB P65、NF-кB P50,和模型组相比,MEL(10 mg/kg)、NAC均能显著降低TNF-α、ICAM-1的表达。
结论
1.连续12周CCl4皮下注射成功复制出大鼠肝纤维化模型,该模型具有典型肝纤维化病理表现,同时符合有关血液、肝组织生化检查改变,适合药物防治肝纤维化的实验研究。
2.MEL具有保护肝细胞、抑制肝纤维化作用,这种作用考虑与其抗氧化有关。
3.NF-кB与肝纤维化关系密切,其表达和DNA结合活性与肝纤维化程度一致,在肝纤维化的发展中起重要作用。
4.MEL保护肝细胞、抑制肝纤维化作用可能部分地与其抑制NF-кB活化,下调NF-кB信号通路有关。
以上结果将为开发MEL作为防治肝纤维化药物提供实验基础。
BACKGROUND/AIMS Hepatic fibrosis, a common pathological process of chronic hepatic disease, can lead to irreversible cirrhosis, and involves multiple cellular and molecular events that ultimately result in accumulation of collagen and extra cellular matrix protein in space of Disse. Hepatic fibrosis generally considered reversible conditions. If treated properly at fibrosis stage, cirrhosis can be prevented. However, no effective antifibrosis drugs are available at present. Therefore , one of important trends focuses on investigation the mechanisms of hepatic fibrosis and exploration new effective drugs without ill effects. Several lines of evidence suggest that oxidative stress plays an important role in the etiopathogenesis of hepatic fibrosis.
Melatonin (N-acetyl-5-metyoxytryptamine), a secretory product of the pineal gland, is a powerful endogenous antioxidant, regulates circadian rhythms, sleep and immune system activity, behaves as a free radical scavenger, eliminates oxygen free radicals and reactive intermediates. Both in vitro and in vivo experiments have shown that melatonin can protect cells, tissues, and organs against oxidative damage induced by a variety of free-radical-generating agents and processes, such as safrole, lipopolysaccharide (LPS), carbon tetrachloride (CCl4), ischemia-reperfusion, amyloid-protein, and ionizing radiation. In addition, melatonin also has an indirect antioxidant effect by enhancing the levels of potential antioxidants such as glutathione peroxidase (GPx), superoxide dismutase (SOD), and glutathione (GSH). Recent studies showed that melatonin reduces fibroblast proliferation and collagen synthesis.
Nuclear factor-kappaB (NF-кB) is a family of dimeric transcription factors that regulate inflammation, innate and adaptive immunity, wound healing respones, and cell fate and function. Physical stress , oxidative stress ,and exposure to certain chemicals can lead to activation of NF-кB , which may function as a critical mediator of stress responses. Excessive activation of NF-кB relates to many diseases.Emerging attention has been focused on the regulation and function of NF-кB during liver injury. NF-кB activation have been implicated as mediators of liver injury and fibrogenesis. The present study was designed to investigate the protective effects of melatonin on carbon tetrachloride (CCl4)-induced hepatic fibrosis in experimental rats and its possible mechanisms. Meanwhile, we evaluated the role of NF-кB on carbon tetrachloride (CCl4)-induced hepatic fibrosis in rats and investigated whether treatment with melatonin was able to modulate NF-kappaB activation.
METHODS All rats were randomly divided into normal control group, model control group treated with CCl4 for 12 wk, CCl4 + NAC group treated with CCl4 + NAC (100 mg/kg, i.p.) for 12 wk, CCl4 + MEL-1 group treated with CCl4 + melatonin (2.5 mg/kg) for 12 wk, CCl4 + MEL-2 group treated with CCl4 + melatonin (5.0 mg/kg) for 12 wk, and CCl4 + MEL-3 group treated with CCl4 + melatonin (10 mg/kg) for 12 wk. Rats in the treatment groups were injected subcutaneously with sterile CCl4 (3 mL/kg, body weight) in a ratio of 2:3 with arachis oil twice a week. Rats in normal control group received hypodermic injection of arachis oil at the same dose and frequency as those in treatment groups. At the end of experiment, rats in each group were anesthetized and sacrificed. Hematoxylin and eosin (HE) staining and Van Gieson staining were used to examine changes in liver pathology. Serum activities of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and protein concentration were measured with routine laboratory methods using an autoanalyzer. Hydroxyproline (Hyp) content in liver and malondialdehyde (MDA) and glutathione peroxidase (GPx) levels in liver homogenates were assayed by spectrophotometry. Serum hyaluronic acid (HA), laminin (LN), and procollagenⅢN-terminal peptide (PⅢNP) were determined by radioimmunoassay. Expression of NF-кB P50 ,NF-кB P65, TNF-αand ICAM-1 in liver tissue was detected by immunohistochemistry and expression of procollagen typeⅠmRNA in liver tissue was detected by semiquantified RT-PCR. NF-kappaB binding activity in liver tissue was determined by electrophoretic mobility shift assay (EMSA). HSCs are isolated from the liver of SD rat through in situ perfusion with pronase and collagenas and they were identified by immunohistochemistry stain with desmin antibody. With LPS and various concentrations of MEL, the inhibition of HSC was determined by MTT method.
RESULTS
1. Protective effects of MEL on chemical hepatic fibrosis induced by CCl4 in rat
The hepatic fibrosis models in rats were successfully induced by CCl4. Pathologic grading showed that the fibrogenesis was much less severe in CCl4 + MEL3 group than in model control group (u = 2.172, P < 0.05), indicating that melatonin (10 mg/kg) can significantly ameliorate CCl4-induced hepatic fibrotic changes. The serum levels of ALT and AST were markedly lower in CCl4 + MEL treatment groups (5, 10 mg/kg) than in model control group. Similarly, melatonin (10 mg/kg) not only decreased hydroxyproline (Hyp) contents in liver , but also decreased the elevated level of laminin (LN) and hyaluronic acid (HA) in serum, which indicate that melatonin decrease the ECM production of hepatic fibrosis in rats. Moreover, melatonin also ameliorated the oxidative stress state of hepatic fibrosis rats. Treatment with melatonin (5, 10 mg/kg) significantly reduced the MDA content and increased the GPx activity in liver homogenates compared with model control group.
2. Effects of MEL on LPS-mediated HSC proliferation
HSCs are successfully isolated from the liver of SD rat through in situ perfusion with pronase and collagenase, crude cell suspensions were purified to 70-80% homogeneity by density gradient centrifugation. The cell viability was more than 90 %. The harvest rate of HSCs was 2×107cells per liver. HSC was identified by immunohistochemistry stain with desmin antibody. The desmin postive cell rate was more than 90 % in subculture.Compared with the control group, LPS (10ng/ml) significantly promoted the proliferation of rat HSCs. Compared with the LPS group, MEL obviously inhibited the proliferation of rat HSCs at the concentration of 0.1mmol/ml.
3. Effect of MEL on hepatic mRNA expressions of procollagen typeⅠ
Compared with normal control group, the expression of procollagen typeⅠm RNA in liver tissue in CCl4-treated groups was significantly increased. Compared with model control group , the expression of procollagen typeⅠmRNA in liver tissue in CCl4 + MEL group(10 mg/kg) and CCl4+NAC group was significantly decreased .
4. The role of NF-кB on hepatic fibrosis induced by CCl4 in rats and the effect of MEL on the NF-кB signaling pathway
Immunohistochemical analysis of liver tissue sections revealed that there were few positive expressions of NF-кB P65, NF-кB P50, TNF-αand ICAM-1 in the normal rat liver. NF-кB P65 and NF-кB P50 expression, as brown or yellow granulae in cytoplasm and nuleus, was apparently increased in response to 12-week subcutaneous injection of CCl4. MEL(5, 10 mg/kg) and NAC significantly reduced NF-кB P65 and NF-кB P50 expression. Meanwhile, expression of TNF-αand ICAM-1 whose transcription are regulated by NF-кB was also apparently increased in response to 12-week subcutaneous injection of CCl4. MEL(10 mg/kg)and NAC significantly reduced TNF-αand ICAM-1 expression. Furthermore, the NF-kappaB-DNA binding activity was confirmed by EMSA. The activation of NF-кB in the normal control group was weak. It was elevated significantly in the model control group. Treatment with melatonin significantly suppressed the NF-кB binding activity in a dose-dependent manner to some degree.
CONCLUSIONS
1. In this study, hepatic fibrosis was successfully induced by subcutaneous injection of sterile CCl4 twice weekly for 12 wk. Through this hepatic fibrosis model, the effects of melatonin on hepatic fibrosis induced by CCl4 in rats were examined.
2. Melatonin may have beneficial effects on hepatic fibrosis induced by CCl4 in rats. The protective effect of melatonin on hepatic fibrosis may be related to its antioxidant activities.
3. NF-кB activation are implicated as mediator of fibrogenesis. NF-кB plays an important role on hepatic fibrosis induced by CCl4 in rats.
4. Melatonin may exert an effect on the inhibition of oxidation stress via downregulation of NF-кB signaling pathway to prevent the progression of hepatic fibrosis.
All above-mentioned research results may provide the experimental basis for melatonin being developed to new drug treating hepatic fibrosis.
肝纤维化是慢性肝病共有的病理特征,其过程涉及到多细胞、多分子事件,最终导致胶原和细胞外基质(extracellular matrix, ECM).在狄氏间隙沉积,并能发展为不可逆性肝硬化。近年来的研究证实,肝纤维化在未进入肝硬化之前,尚有逆转可能。在此阶段,如果处理得当,肝硬化有可能避免。然而,目前尚无理想的治疗肝纤维化药物。因此,探讨肝纤维化的机理,开发有效和毒副作用小的治疗肝纤维化的新药是目前研究的重要方向。目前有证据提示,氧化应激在肝纤维化的发生和发展中起重要作用。
褪黑素(N-acetyl-5-metyoxytryptamine, melatonin)是松果体分泌的一种激素,为强大的内源性抗氧化剂,能清除氧自由基和中间活性体。体内和体外实验显示,在由黄樟素、脂多糖(LPS)、四氯化碳(CCl4)、缺血再灌注、淀粉状蛋白质、电离辐射等诱导的氧化损伤中,褪黑素具有保护细胞、组织和器官的作用。另外,褪黑素还通过提高谷胱甘肽过氧化物酶(GPx)、超氧化物歧化酶(SOD)、谷胱甘肽(GSH)这些潜在性的抗氧化剂的水平而间接发挥抗氧化作用。近年研究显示,褪黑素具有减少纤维母细胞增殖、抑制胶原合成作用。但褪黑素对肝纤维化的保护作用研究尚少。
核转录因子кB(Nuclear factor-kappaB ,NF-кB)是由二聚体构成的转录因子家族,具有调控炎症、免疫、创伤愈合、细胞生存、细胞功能等作用。生理应激、氧化应激、暴露于某些化学品均可导致NF-кB激活,进而发挥其关键性的应激反应调节作用。NF-кB过度激活与许多疾病有关。近来NF-кB在肝脏疾病中的功能和调控受到关注,肝脏的损伤和纤维增生涉及到NF-кB的活化。NF-кB在肝纤维化中的确切作用尚不甚清楚,褪黑素对纤维化肝脏中NF-кB活性的影响及其后果未见系统研究。本课题在建立大鼠CCl4诱导的化学性肝纤维化模型基础上,探讨MEL对肝纤维化的抑制作用和可能机制。同时,探讨NF-кB在CCl4诱导的化学性肝纤维化中的作用,以及MEL是否通过抑制NF-кB活性而发挥抗纤维化作用。
方法
采用四氯化碳(carbon tetrachloride ,CCl4)制备SD大鼠化学性肝纤维化模型。所有大鼠随机分为6组:正常对照组(normal control group,normal组,11只)、模型对照组(model control group, model组,20只)、CCl4+N-乙酰-L-半胱氨酸组(NAC组,为阳性药对照,20只)、CCl4+低剂量褪黑素组(MEL1组,20只)、CCl4+中剂量褪黑素组(MEL2组,20只)、CCl4+高剂量褪黑素组(MEL3组,20只)。将CCl4与精制花生油按2 :3比例配成40%CCl4油剂溶液,除正常对照组外,余按3ml/kg给大鼠皮下注射,每周两次,连续12周,正常对照组注射等容量花生油作为对照。自动物皮下注射CCl4之日起,开始给药, NAC 100 mg/kg, i.p.,每天1次;MEL低、中、高剂量组分别给予MEL 2.5 mg/kg、5 mg/kg、10 mg/kg,均为腹腔注射。12周实验结束后,所有动物予以麻醉,腹主动脉取血,取出肝脏并称湿重。HE染色和Van Gieson (VG)胶原纤维染色观察肝脏病理改变;全自动生化分析仪检测血清谷丙转氨酶(alanine aminotransferase, ALT)、谷草转氨酶(aspartate aminotransferase ,AST)、白蛋白(albumin, A)、球蛋白(globulin, G )水平;生化法测定肝脏羟脯氨酸(hydroxyproline ,Hyp)、丙二醛(malondialdehyde ,MDA)含量和谷胱甘肽过氧化物酶活性(glutathione peroxidase ,GPx);放射免疫法测定血清透明质酸(hyaluronic acid,HA)、层粘连蛋白(laminin,LN)、三型前胶原氨端肽(procollagenⅢN-terminal peptide,PⅢN P)含量;免疫组化法测定肝组织中NF-кB P50、NF-кB P65、肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)、细胞间粘附分子-1(Intercellular adhesion molecule-1,ICAM-1)的表达;RT-PCR法测定肝组织中Ⅰ型前胶原(procollagen typeⅠ)mRNA表达;电泳迁移率改变分析(electrophoretic mobility shift assay ,EMSA)测定肝组织中NF-кB DNA结合活性;同时,用原位灌注加密度梯度离心法分离正常SD大鼠肝脏星状细胞,以免疫组化法鉴定(用desmin抗体),在培养的肝星状细胞中加入脂多糖(LPS)进行刺激,用MTT法测定不同浓度的MEL对肝星状细胞增殖的抑制作用。
结果
1. MEL对大鼠化学性肝纤维化的保护作用
通过12周皮下注射CCl4,成功建立了大鼠肝纤维化模型。病理分级显示:正常对照组和CCl4处理各组之间差异显著(P < 0.01),和模型组相比,MEL(10 mg/kg)组肝纤维化程度较轻,有统计学意义(P < 0.05),表明MEL(10 mg/kg)有抑制肝纤维化作用。与正常对照组比较,CCl4处理各组血清ALT、AST水平显著升高(P < 0.01),与模型组比较,MEL(5, 10 mg/kg)能显著降低升高的的ALT、AST水平(P < 0.05,P < 0.01),NAC也能显著降低升高的ALT、AST水平(P < 0.05),其作用强度和MEL相近。同样,与模型组比较,MEL(10 mg/kg)能降低肝脏Hyp含量和LN、HA水平,表明MEL对纤维化标志物的改善。另外,MEL对氧化应激指标也有明显影响,和模型组比较,MEL(5, 10 mg/kg)能显著降低肝匀浆MDA含量(P < 0.05),升高GPx活性(P < 0.05,P < 0.01),NAC也有同样作用,其作用强度和MEL(10 mg/kg)相近。
2. MEL对LPS介导的肝星状细胞增殖的影响
通过原位灌注和密度梯度离心法成功分离并纯化大鼠肝星状细胞,刚分离的星状细胞纯化至70-80%,存活率在90 %以上,纯化的星状细胞得率2×107/肝。传第一代的细胞,S-P法作免疫细胞化学鉴定,Desmin表达阳性细胞为90%以上。与对照组(无LPS刺激)相比,培养的肝星状细胞经LPS(10ng/ml)刺激后,增殖明显加快,与LPS组相比, MEL(0.1mmol/L)能显著抑制由LPS刺激的肝星状细胞增殖。
3. MEL对纤维化大鼠肝组织I型前胶原mRNA表达的影响
正常对照组大鼠肝组织I型前胶原mRNA表达较少,和CCl4处理各组相比,差异显著(P<0.05,P<0.01)。和模型组相比,MEL(10 mg/kg)组、NAC组表达明显减少(P<0.05),MEL(2.5 mg/kg, 5 mg/kg)表达有下降趋势,但无统计学意义。这些结果表明MEL有抑制肝脏纤维化大鼠I型前胶原mRNA表达作用。
4. NF-кB在CCl4诱导的大鼠肝纤维化中的作用以及MEL对NF-кB信号通路的影响
NF-кB P65、NF-кB P50在正常对照组大鼠肝组织中仅有微量表达,表现为细胞浆中淡黄色颗粒,较之正常对照组,CCl4处理各组表达明显增强,表现为棕黄色和/或棕褐色颗粒,且细胞浆和细胞核中均有表达,和模型组相比,MEL(5, 10 mg/kg)、NAC均能显著降低NF-кB P65、NF-кB P50的表达。进一步, NF-кB DNA结合活性被测定,结果显示,正常对照组NF-кB结合活性较弱,模型组NF-кB结合活性较其它各组明显增强,和模型组相比,MEL能明显抑制NF-кB的结合活性。
TNF-α、ICAM-1在正常对照组大鼠肝组织中仅很微量表达,表现为细胞浆中淡黄色颗粒,较之正常对照组,CCl4处理各组表达明显增强,表现为棕黄色和/或棕褐色颗粒,以血管周围,汇管区炎性细胞较多的区域最为明显,其表达强度弱于NF-кB P65、NF-кB P50,和模型组相比,MEL(10 mg/kg)、NAC均能显著降低TNF-α、ICAM-1的表达。
结论
1.连续12周CCl4皮下注射成功复制出大鼠肝纤维化模型,该模型具有典型肝纤维化病理表现,同时符合有关血液、肝组织生化检查改变,适合药物防治肝纤维化的实验研究。
2.MEL具有保护肝细胞、抑制肝纤维化作用,这种作用考虑与其抗氧化有关。
3.NF-кB与肝纤维化关系密切,其表达和DNA结合活性与肝纤维化程度一致,在肝纤维化的发展中起重要作用。
4.MEL保护肝细胞、抑制肝纤维化作用可能部分地与其抑制NF-кB活化,下调NF-кB信号通路有关。
以上结果将为开发MEL作为防治肝纤维化药物提供实验基础。
BACKGROUND/AIMS Hepatic fibrosis, a common pathological process of chronic hepatic disease, can lead to irreversible cirrhosis, and involves multiple cellular and molecular events that ultimately result in accumulation of collagen and extra cellular matrix protein in space of Disse. Hepatic fibrosis generally considered reversible conditions. If treated properly at fibrosis stage, cirrhosis can be prevented. However, no effective antifibrosis drugs are available at present. Therefore , one of important trends focuses on investigation the mechanisms of hepatic fibrosis and exploration new effective drugs without ill effects. Several lines of evidence suggest that oxidative stress plays an important role in the etiopathogenesis of hepatic fibrosis.
Melatonin (N-acetyl-5-metyoxytryptamine), a secretory product of the pineal gland, is a powerful endogenous antioxidant, regulates circadian rhythms, sleep and immune system activity, behaves as a free radical scavenger, eliminates oxygen free radicals and reactive intermediates. Both in vitro and in vivo experiments have shown that melatonin can protect cells, tissues, and organs against oxidative damage induced by a variety of free-radical-generating agents and processes, such as safrole, lipopolysaccharide (LPS), carbon tetrachloride (CCl4), ischemia-reperfusion, amyloid-protein, and ionizing radiation. In addition, melatonin also has an indirect antioxidant effect by enhancing the levels of potential antioxidants such as glutathione peroxidase (GPx), superoxide dismutase (SOD), and glutathione (GSH). Recent studies showed that melatonin reduces fibroblast proliferation and collagen synthesis.
Nuclear factor-kappaB (NF-кB) is a family of dimeric transcription factors that regulate inflammation, innate and adaptive immunity, wound healing respones, and cell fate and function. Physical stress , oxidative stress ,and exposure to certain chemicals can lead to activation of NF-кB , which may function as a critical mediator of stress responses. Excessive activation of NF-кB relates to many diseases.Emerging attention has been focused on the regulation and function of NF-кB during liver injury. NF-кB activation have been implicated as mediators of liver injury and fibrogenesis. The present study was designed to investigate the protective effects of melatonin on carbon tetrachloride (CCl4)-induced hepatic fibrosis in experimental rats and its possible mechanisms. Meanwhile, we evaluated the role of NF-кB on carbon tetrachloride (CCl4)-induced hepatic fibrosis in rats and investigated whether treatment with melatonin was able to modulate NF-kappaB activation.
METHODS All rats were randomly divided into normal control group, model control group treated with CCl4 for 12 wk, CCl4 + NAC group treated with CCl4 + NAC (100 mg/kg, i.p.) for 12 wk, CCl4 + MEL-1 group treated with CCl4 + melatonin (2.5 mg/kg) for 12 wk, CCl4 + MEL-2 group treated with CCl4 + melatonin (5.0 mg/kg) for 12 wk, and CCl4 + MEL-3 group treated with CCl4 + melatonin (10 mg/kg) for 12 wk. Rats in the treatment groups were injected subcutaneously with sterile CCl4 (3 mL/kg, body weight) in a ratio of 2:3 with arachis oil twice a week. Rats in normal control group received hypodermic injection of arachis oil at the same dose and frequency as those in treatment groups. At the end of experiment, rats in each group were anesthetized and sacrificed. Hematoxylin and eosin (HE) staining and Van Gieson staining were used to examine changes in liver pathology. Serum activities of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and protein concentration were measured with routine laboratory methods using an autoanalyzer. Hydroxyproline (Hyp) content in liver and malondialdehyde (MDA) and glutathione peroxidase (GPx) levels in liver homogenates were assayed by spectrophotometry. Serum hyaluronic acid (HA), laminin (LN), and procollagenⅢN-terminal peptide (PⅢNP) were determined by radioimmunoassay. Expression of NF-кB P50 ,NF-кB P65, TNF-αand ICAM-1 in liver tissue was detected by immunohistochemistry and expression of procollagen typeⅠmRNA in liver tissue was detected by semiquantified RT-PCR. NF-kappaB binding activity in liver tissue was determined by electrophoretic mobility shift assay (EMSA). HSCs are isolated from the liver of SD rat through in situ perfusion with pronase and collagenas and they were identified by immunohistochemistry stain with desmin antibody. With LPS and various concentrations of MEL, the inhibition of HSC was determined by MTT method.
RESULTS
1. Protective effects of MEL on chemical hepatic fibrosis induced by CCl4 in rat
The hepatic fibrosis models in rats were successfully induced by CCl4. Pathologic grading showed that the fibrogenesis was much less severe in CCl4 + MEL3 group than in model control group (u = 2.172, P < 0.05), indicating that melatonin (10 mg/kg) can significantly ameliorate CCl4-induced hepatic fibrotic changes. The serum levels of ALT and AST were markedly lower in CCl4 + MEL treatment groups (5, 10 mg/kg) than in model control group. Similarly, melatonin (10 mg/kg) not only decreased hydroxyproline (Hyp) contents in liver , but also decreased the elevated level of laminin (LN) and hyaluronic acid (HA) in serum, which indicate that melatonin decrease the ECM production of hepatic fibrosis in rats. Moreover, melatonin also ameliorated the oxidative stress state of hepatic fibrosis rats. Treatment with melatonin (5, 10 mg/kg) significantly reduced the MDA content and increased the GPx activity in liver homogenates compared with model control group.
2. Effects of MEL on LPS-mediated HSC proliferation
HSCs are successfully isolated from the liver of SD rat through in situ perfusion with pronase and collagenase, crude cell suspensions were purified to 70-80% homogeneity by density gradient centrifugation. The cell viability was more than 90 %. The harvest rate of HSCs was 2×107cells per liver. HSC was identified by immunohistochemistry stain with desmin antibody. The desmin postive cell rate was more than 90 % in subculture.Compared with the control group, LPS (10ng/ml) significantly promoted the proliferation of rat HSCs. Compared with the LPS group, MEL obviously inhibited the proliferation of rat HSCs at the concentration of 0.1mmol/ml.
3. Effect of MEL on hepatic mRNA expressions of procollagen typeⅠ
Compared with normal control group, the expression of procollagen typeⅠm RNA in liver tissue in CCl4-treated groups was significantly increased. Compared with model control group , the expression of procollagen typeⅠmRNA in liver tissue in CCl4 + MEL group(10 mg/kg) and CCl4+NAC group was significantly decreased .
4. The role of NF-кB on hepatic fibrosis induced by CCl4 in rats and the effect of MEL on the NF-кB signaling pathway
Immunohistochemical analysis of liver tissue sections revealed that there were few positive expressions of NF-кB P65, NF-кB P50, TNF-αand ICAM-1 in the normal rat liver. NF-кB P65 and NF-кB P50 expression, as brown or yellow granulae in cytoplasm and nuleus, was apparently increased in response to 12-week subcutaneous injection of CCl4. MEL(5, 10 mg/kg) and NAC significantly reduced NF-кB P65 and NF-кB P50 expression. Meanwhile, expression of TNF-αand ICAM-1 whose transcription are regulated by NF-кB was also apparently increased in response to 12-week subcutaneous injection of CCl4. MEL(10 mg/kg)and NAC significantly reduced TNF-αand ICAM-1 expression. Furthermore, the NF-kappaB-DNA binding activity was confirmed by EMSA. The activation of NF-кB in the normal control group was weak. It was elevated significantly in the model control group. Treatment with melatonin significantly suppressed the NF-кB binding activity in a dose-dependent manner to some degree.
CONCLUSIONS
1. In this study, hepatic fibrosis was successfully induced by subcutaneous injection of sterile CCl4 twice weekly for 12 wk. Through this hepatic fibrosis model, the effects of melatonin on hepatic fibrosis induced by CCl4 in rats were examined.
2. Melatonin may have beneficial effects on hepatic fibrosis induced by CCl4 in rats. The protective effect of melatonin on hepatic fibrosis may be related to its antioxidant activities.
3. NF-кB activation are implicated as mediator of fibrogenesis. NF-кB plays an important role on hepatic fibrosis induced by CCl4 in rats.
4. Melatonin may exert an effect on the inhibition of oxidation stress via downregulation of NF-кB signaling pathway to prevent the progression of hepatic fibrosis.
All above-mentioned research results may provide the experimental basis for melatonin being developed to new drug treating hepatic fibrosis.
引文
1. Friedman SL. Liver fibrosis– from bench to beside. J Hepatol, 2003; 38 Suppl 1:S38-53
2. Lotersztajn S, Julien B, Teixeira-Clerc F, Grenard P, Mallat A. Hepatic fibrosis: molecular mechanisms and drug targets. Annu Rev Pharmacol Toxicol. 2005;45:605-28
3. Pinzani M. Therapies for hepatic fibrosis: real hope or just academic exercise? Dig Liver Dis. 2004;36:714-716
4. Mann DA, Smart DE. Transcriptional regulation of hepatic stellate cell activation. Gut, 2002; 50:891-896
5.尤红,王宝恩.核因子-кB在肝脏疾病中研究进展.临床肝胆杂志,2000;16:11-12
6. Aboutwerat A, Pemberton PW, Smith A, Burrows PC, McMahon RF, Jain SK, Warnes TW. Oxidant stress is a significant feature of primary biliary cirrhosis.Biochim Biophys Acta 2003;1637:142-150
7. Koruk M,Aksoy H,Akcay F,et al.Antioxidant capacity and nitric oxide in patients with hepatic cirrhosis.Ann Clin Lab Sci 2002;32:252-256.
8. Kitada T, Seki S, Iwai S, Yamada T, Sakaguchi H, Wakasa K. In situ detection of oxidative DNA damage, 8-hydroxydeoxyguanosine, in chronic human liver disease. J Hepatol. 2001;35: 613-618
9. Yang S, Tan TM, Wee A, Leow CK. Mitochondrial respiratory function and antioxidant capacity normal and cirrhosis livers following partial hepatectomy.Cell Mol Life Sci 2004;61:220-229.
10. Parola M,Robino G. Oxidative stress-related molecules and liver fibrosis.Journal of Hepatology, 2001;35:297-306.
11. Poli G.. Pathogenesis of liver fibrosis:role of oxidative stress.Molecular Aspects ofMedicine 2000;21:49-98.
12. Hernández-Mu?oz R, Díaz-Mu?oz M, Suárez-Cuenca JA, Trejo-Solís C, López V, Sánchez-Sevilla L, Yá?ez L, De Sánchez VC.Adenosine reverses a preestablished CCl4-induced micronodular cirrhosis through enhancing collagenolytic activity and stimulating hepatocyte cell proliferation in rats.Hepatology 2001;34:677-687.
13. Lieber CS, Leo MA, Cao Q, Ren C, DeCarli LM. Silymarin retards the progression of alcohol-induced hepatitis in baboons.J Clin Gastroenterol 2003;37:336-339.
14. Wasser S, Lim GY, Ong CN, Tan CE. Anti-oxidant ebselen causes the resolution of experimentally induced hepatic fibrosis in rats. J Gastroenterol Hepatol 2001;16:1244-1253.
15. Bruck R, Shirin H, Aeed H, Matas Z, Hochman A, Pines M, Avni Y. Prevention of hepatic cirrhosis in rats by hydroxyl radicals scavengers. J Hepatol 2001;35:457-464.
16. . Rozov SV, Filatova EV, Orlov AA, Volkova AV, Zhloba AR, Blashko EL, Pozdeyev NV. N1-acetyl-N2-formyl-5-methoxykynuramine is a product of melatonin oxidation in rats. J Pineal Res 2003; 35:245-250.
17. Sener-Murato?lu G, Paskalo?lu K, Arbak S, Hürda? C, Ayano?lu-Dülger G.. Protective effect of famotidine, omeprazole, and melatonin against acetylsalicylic acid-induced gastric damage in rats. Dig Dis Sci 2001; 46:318-330.
18. Tahan V, Ozaras R, Canbakan B, Uzun H, Aydin S, Yildirim B, Aytekin H, Ozbay G, Mert A, Senturk H. Melatonin reduces dimethylnitrosamine-induced liver fibrosis in rats. J Pineal Res 2004;37:78-84.
19. Ohta Y, Kongo-Nishimura M, Matsura T, Yamada K, Kitagawa A, Kishikawa T. Melatonin prevents disruption of hepatic reactive oxygen species metabolism in rats treated with carbon tetrachloride. J Pineal Res 2004; 36:10-17.
20. Chen JC, Ng CJ, Chiu TF, Chen HM. Altered neutrophil apoptosis activity is reversed by melatonin in liver ischemeia-reperfusion. J Pineal Res 2003;34:260-264.
21. Taysi S, Koc M, Büyükokuro?lu ME, Altinkaynak K, Sahin YN. Melatonin reduces lipid peroxidation and nitric oxide during irradiation induced oxidative injury in the rat liver. J Pineal Res 2003; 34:173-177.
22. Padillo FJ, Cruz A, Navarrete C, Bujalance I, Brice?o J, Gallardo JI, Marchal T, Caballero R, Túnez I, MuntanéJ, Montilla P, Pera-Madrazo C. Melatonin prevents oxidative stress and hepatocyte cell death induced by experimental cholestasis. Free Radic Res 2004; 38:697-704.
23. Zavodnik LB, Zavodnik IB, Lapshina EA, Belonovskaya EB, Martinchik DI, Kravchuk RI, Bryszewska M, Reiter RJ. Protective effects of melatonin against carbon tetrachloride hepatotoxicity in rats. Cell Biochemistry Function 2005;23:353-359.
24. Cruz A, Padillo FJ, Torres E, Navarrete CM, Mu?oz-Casta?eda JR, Caballero FJ, Brice?o J, Marchal T, Túnez I, Montilla P, Pera C, MuntanéJ.Melatonin prevents experiments liver cirrhosis induced by thioacetamide in rats.Journal of Pineal Research 2005; 39:143-150.
25. Tahan V, Ozaras R, Canbakan B, Uzun H, Aydin S, Yildirim B, Aytekin H, Ozbay G, Mert A, Senturk H. Melatonin reduces dimethylnitrosamine-induced liver fibrosis in rats. J Pineal Res 2004;37:78-84.
26. Natarajan M, Reiter RJ, Meltz ML, Herman TS. Effect of melatonin on cell growth, metabolic activity, and cell cycle distribution. J Pineal Res. 2001 ;31:228-233
27. Lezoualc'h F, Sparapani M, Behl C. N-acetyl-serotonin (normelatonin) and melatonin protect neurons against oxidative challenges and suppress the activity of the transcription factor NF-kappaB. J Pineal Res. 1998 ;24:168-178
28. Nava M, Quiroz Y, Vaziri N, Rodriguez-Iturbe B. Melatonin reduces renal interstitial inflammation and improves hypertension in spontaneously hypertensive rats. Am J Physiol Renal Physiol. 2003 ; 284:F447-454
29. Wang H, Wei W, Wang NP, Gui SY, Wu L, Sun WY, Xu SY. Melatonin ameliorates carbon tetrachloride-induced hepatic fibrogenesis in rats via inhibition of oxidative stress. Life Sci. 2005;77:1902-1915
30. Brenner DA. Signal transduction during liver regeneration. J Gastroenterol Hepatol. 1998 ;13 Suppl:S93-95
31. Zhang LJ, Yu JP, Li D, Huang YH, Chen ZX, Wang XZ. Effects of cytokines on carbon tetrachloride-induced hepatic fibrogenesis in rats. World J Gastroenterol. 2004;10:77-81
32. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13: 372-374
33. Wu J, Norton PA. Animal models of liver fibrosis. Scand J Gastroenterol 1996; 31: 1137-1143
34. Ohta Y, Kongo M, Sasaki E, Nishida K, Ishiguro I. Therapeutic effect of melatonin on carbon tetrachloride-induced acute liver injury in rats. J Pineal Res. 2000 ;28:119-126
35. Do?ru-Abbaso?lu S, Balkan J, Kanba?li O, Cevikba? U, Ayka?-Toker G, Uysal M. Aminoguanidine, an inducible nitric oxide synthase inhibitor, plus N-acetylcysteine treatment reduce the lipopolysaccharide-augmented hepatotoxicity in rats with cirrhosis . Hum Exp Toxicol 2002;21:359-364.
36. Vendemiale G, Grattagliano I, Caruso ML, Serviddio G, Valentini AM, Pirrelli M, Altomare E.. Increased oxidative sterss in dimethylnitrosamine-induced liver fibrosis in the rat:effect of N-acetylcysteine and interferon-alpha . Toxicol Appl Pharmacol, 2001; 175:130-139
37. Lee HJ, Oh YK, Rhee M, Lim JY, Hwang JY, Park YS, Kwon Y, Choi KH, Jo I, Park SI, Gao B, Kim WH. The role of STAT1/IRF-1 on synergistic ROS production and loss of mitochondrial transmembrane potential during hepatic cell death induced by LPS/d-GalN. J Mol Biol. 2007 ;369:967-984
38. Kim KY, Rhim T, Choi I, Kim SS. N-acetylcysteine induces cell cycle arrest in hepatic stellate cells through its reducing activity. J Biol Chem 2001; 276:40591-40598
39.乔玲,李亚明. N-乙酰半胱氨酸的作用机制和在肝病中的应用.医学综述,2007;13:39～40
40. Majano PL, Medina J, Zubía I, Sunyer L, Lara-Pezzi E, Maldonado-Rodríguez A, López-Cabrera M, Moreno-Otero R. N-Acetyl-cysteine modulates inducible nitric oxide synthase gene expression in human hepatocytes. J Hepatol. 2004 ;40:632-637
41. Zafarullah M, Li WQ, Sylvester J, Ahmad M. Molecular mechanisms of N-acetylcysteine actions. Cell Mol Life Sci. 2003 ;60:6-20
42. Serviddio G, Pereda J, PallardóFV, Carretero J, Borras C, Cutrin J, Vendemiale G, Poli G, Vi?a J, Sastre J. Ursodeoxycholic acid protects against secondary biliarycirrhosis in rats by preventing mitochondrial oxidative stress. Hepatology 2004; 39: 711-720
43. Lu G, Shimizu I, Cui X, Itonaga M, Tamaki K, Fukuno H, Inoue H, Honda H, Ito S. Antioxidant and antiapoptotic activities of idoxifene and estradiol in hepatic fibrosis in rats. Life Sci 2004; 74: 897-907
44. Geesin JC, Hendricks LJ, Falkenstein PA, Gordon JS, Berg RA. Regulation of collagen synthesis by ascorbic acid: characterization of the role of ascorbate-stimulated lipid peroxidation. Arch Biochem Biophys 1991; 290: 127-132
45. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115: 209-218
46. Gressner AM, Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med 2006; 10: 76-99
47. Brzezinski A. Melatonin in human. N Engl J Med 1997;336:186-195
48. Messner M, Huether G, Lorf T, Ramadori G, Schw?rer H. Presence of melatonin inthe human hepatobiliary-gastrointestinal tract. Life Sci. 2001 ;69:543-551
49. Cristina Tomás-Zapico, Ana Coto-Montes. Melatonin as antioxidant under pathological processes. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery 2007;1:63-82
50. Sener G, Jahovic N, Tosun O, Atasoy BM, Ye?en BC. Melatonin ameliorates ionizing radiation-induced oxidative organ damage in rats. : Life Sci. 2003 ;74:563-572
51. LB Zavodnik, IB Zavodnik, EA Lapshina, EB Belonovskaya, DI Martinchik, RI Kravchuk, M Bryszewska, RJ Reiter. Protective effects of melatonin against carbon tetrachloride hepatotoxicity in rats. Cell Biochemistry Function 2005;23:353-359
52. Liu F, Ng TB. Effect of pineal indoles on activities of the antioxidant defense enzymes superoxide dismutase, catalase, and glutathione reductase,and levels of reduced and oxidized glutathione in rat tissues. Biochem Cell Biol 2000;78:447-453
53.甄允方,孙庆林,顾志成,汪健.褪黑素对大鼠肝缺血再灌注损伤的保护作用.苏州大学学报(医学版),2007;27:41-42
54.周学武金国安罗春芬陈青江.褪黑素对大鼠肝缺血再灌注损伤的保护作用研究.浙江医学2006,28:642-644
55. El-Missiry MA, Fayed TA, El-Sawy MR, El-Sayed AA. Ameliorative effect of melatonin against gamma-irradiation-induced oxidative stress and tissue injury. Ecotoxicology and Environmental Safety 2007;66:278-86.
56. Montilla P, Cruz A, Padillo FJ, Túnez I, Gascon F, Mu?oz MC, Gómez M, Pera C. Melatonin versus vitamin E as protective treatment against oxidative stress after extra-hepatic bile duct ligation in rats. J Pineal Res. 2001 ;31:138-144
57. Ohta Y, Kongo M, Kishikawa T. Melatonin exerts a therapeutic effect on cholestatic liver injury in rats with bile duct ligation. J Pineal Res 2003;34:119-126
58. Padillo FJ, Cruz A, Navarrete C, Bujalance I, Brice?o J, Gallardo JI, Marchal T,Caballero R, Túnez I, MuntanéJ, Montilla P, Pera-Madrazo C. Melatonin prevents oxidative stress and hepatocyte cell death induced by experimental cholestasis. Free Radic Res 2004;38:697-704
59. Serviddio G, Pereda J, PallardóFV, Carretero J, Borras C, Cutrin J, Vendemiale G, Poli G, Vi?a J, Sastre J.Ursodeoxycholic acid protects against secondary biliary cirrhosis in rats by preventing mitochondrial oxidative stress. Hepatology 2004; 39: 711-720
60. El-Sokkary GH, Abdel-Rahman GH, Kamel ES. Melatonin protects against lead-induced hepatic and renal toxicity in male rats. Toxicology 2005;213:25-33.
61. Sigala F, Theocharis S, Sigalas K, Markantonis-Kyroudis S, Papalabros E, Triantafyllou A, Kostopanagiotou G, Andreadou I. Therapeutic value of melatonin in an experimental model of liver injury and regeneration. J Pineal Res 2006;40:270-279
62. Wang H, Xu DX, Lv JW, Ning H, Wei W. Melatonin attenuates lipopolysaccharide (LPS)-induced apoptotic liver damage in D-galactosamine-sensitized mice. Toxicology, 2007 ;237:49-57
63. Ostrowska Z, Swientochowska E, Buntner B, Marek B, Zwirska-Korczala K, Spyra Z, Banas I I. Assessment of relationship between secretion of melatonin,activity of thyroid, adrenal cortex as well as testes and chosen markers of collagen metabolism in starved rats. Endocrine Regulations 1996;30:83-92
64. Cunnane SC, Manku MS, Horrobin DF. The pineal and regulation of fibrosis: pinealectomy as a model of primary biliary cirrhosis: roles of melatonin and prostaglandins in fibrosis and regulation of T lymphocytes. Medical Hypotheses 1979; 5:403-414.
65.许建明,徐叔云,梅俏,丁长海,沈玉先.褪黑素对小鼠免疫性肝损伤的保护作用.中国药理学通报,1998;14:452-454
66.王华沈玉先魏伟董晨汪倪萍张玲玲岳莉.褪黑素对免疫性肝损伤小鼠自由基和细胞因子的影响.中国药理学通报2002;18:331-334
67.王映梅,李青,闫庆国,惠延平,马福成,胡沛臻.褪黑素对大鼠酒精性肝纤维化的作用.中国临床康复, 2006;10:74-76
68.刘卫辉,蔡川,周扬,刘芳娥,田少华.褪黑素对乙醇致小鼠慢性肝损伤的保护作用.第四军医大学学报,2006;27:1665-1667
69. Iba?ez P, Solis N, Pizarro M, Aguayo G, Duarte I, Miquel JF, Accatino L, Arrese M. Effect of losartan on early liver fibrosis development in a rat model of nonalcoholic steatohepatitis. J Gastroenterol Hepatol. 2007 ;22:846-851
70. Dang SS, Wang BF, Cheng YA, Song P, Liu ZG, Li ZF. Inhibitory effects of saikosaponin-d on CCl4-induced hepatic fibrogenesis in rats. World J Gastroenterol. 2007; 13: 557-563
71. Qiu JF, Zhang ZQ, Chen W, Wu ZY. Cystamine ameliorates liver fibrosis induced by carbon tetrachloride via inhibition of tissue transglutaminase. World J Gastroenterol 2007 ; 13: 4328-4332
72. Kaneda H, Hashimoto E, Yatsuji S, Tokushige K, Shiratori K. Hyaluronic acid levels can predict severe fibrosis and platelet counts can predict cirrhosis in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol 2006; 21: 1459-1465
73. Yin MF, Lian LH, Piao DM, Nan JX. Tetrandrine stimulates the apoptosis of hepatic stellate cells and ameliorates development of fibrosis in a thioacetamide rat model. World J Gastroenterol. 2007 ;13:1214-1220
74. Kaneda H, Hashimoto E, Yatsuji S, Tokushige K, Shiratori K. Hyaluronic acid levels can predict severe fibrosis and platelet counts can predict cirrhosis in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol. 2006;21:1459-1465.
75. Tamura T, Kobayashi H, Yamataka A, Lane GJ, Koga H, Miyano T. Inchin-ko-to prevents medium-term liver fibrosis in postoperative biliary atresia patients. Pediatr Surg Int. 2007;23:343-347
76. Suzuki A, Angulo P, Lymp J, Li D, Satomura S, Lindor K. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease. Liver Int. 2005;25:779-786
77. Li CH, Pan LH, Yang ZW, Li CY, Xu WX. Preventive effect of Qianggan-Rongxian Decoction on rat liver fibrosis. World J Gastroenterol. 2008;14:3569-3573
78. Fontana RJ, Goodman ZD, Dienstag JL, Bonkovsky HL, Naishadham D, Sterling RK, Su GL, Ghosh M, Wright EC; HALT-C Trial Group. Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology 2008 ;47:789-798
79. Khan JA, Khan FA, Dilawar M, Ijaz A, Khan NA, Mehmood T. Serum hyaluronic acid as a marker of hepatic. J Coll Physicians Surg Pak. 2007;17:323-326
80. He YT, Liu DW, Ding LY, Li Q, Xiao YH. Therapeutic effects and molecular mechanisms of anti-fibrosis herbs and selenium on rats with hepatic fibrosis. World J Gastroenterol. 2004 ;10:703-706
81. Wang H, Wei W, Wang NP, Wu CY, Yan SX, Yue L, Zhang LL, Xu SY. Effects of total glucosides of peony on immunological hepatic fibrosis in rats. World J Gastroenterol. 2005;11:2124-2129
82. Li CH, Piao DM, Xu WX, Yin ZR, Jin JS, Shen ZS. Morphological and serum hyaluronic acid, laminin and type IV collagen changes in dimethylnitrosamine- induced hepatic fibrosis of rats. World J Gastroenterol. 2005;11:7620-7624
83. Yang YY, Huang YT, Lee KC, Lee FY, Lee TY, Hou MC, Lin HC, Lee SD. Chronic administration of ursodeoxycholic acid decreases portal pressure in rats with biliary cirrhosis. Clin Sci (Lond). 2009 ;116:71-79
84. Koivisto H, Hietala J, Niemel? O. An inverse relationship between markers of fibrogenesis and collagen degradation in patients with or without alcoholic liver disease. Am J Gastroenterol. 2007;102:773-779
85. Trocme C, Leroy V, Sturm N, Hilleret MN, Bottari S, Morel F, Zarski JP.Longitudinal evaluation of a fibrosis index combining MMP-1 and PIIINP compared with MMP-9, TIMP-1 and hyaluronic acid in patients with chronic hepatitis C treated by interferon-alpha and ribavirin. J Viral Hepat. 2006; 13:643- 651
86. Kamal SM, Turner B, He Q, Rasenack J, Bianchi L, Al Tawil A, Nooman A, Massoud M, Koziel MJ, Afdhal NH. Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosis. Hepatology 2006;43:771-779
87. Drewa G, Krzyzyńska-Malinowska E, Wo?niak A, Protas-Drozd F, Mila-Kierzenkowska C, Rozwodowska M, Kowaliszyn B, Czajkowski R. Activity of superoxide dismutaseand and catalase and the level of lipid peroxidation products reactive with TBA in patients with psoriasis. Med Sci Monit 2002; 8: BR338-BR343
88. Ajamieh HH, Menéndez S, Martínez-Sánchez G, Candelario-Jalil E, Re L, Giuliani A, Fernández OS. Effects of ozone oxidative preconditioning on nitric oxide generation and cellular redox balance in a rat model of hepatic ischemia- reperfusion. Liver Int 2004; 24: 55-62
89. Shimizu I, Ma YR, Mizobuchi Y, Liu F, Miura T, Nakai Y, Yasuda M, Shiba M, Horie T, Amagaya S, Kawada N, Hori H, Ito S. Effect of Sho-saikoto, a Japanese herbal medicine, on hepatic fibrosis in rats. Hepatology 1999; 29:149-160
90. Zhou X, Murphy FR, Gehdu N, Zhang J, Iredale JP, Benyon RC.Engagement of aintegrin regulates proliferation and apoptosis of hepatic stellate cells.J Biol Chem,2004,279(23):23996-24006
91.王健,牛建昭,河福金,于世赢,白锦文,李或,赵丽云,赵福建,王继峰.脂多糖诱导大鼠肝星状细胞增殖与提高其胶原表达水平的细胞模型研究中西医结合肝病杂志2003;13:92-93
92.王卫卫,杨希山,李旭,王捷,田野,赖晃文,杨传红,赖日权.洛沙坦对肝纤维化大鼠AngⅡ1型受体的表达及胶原形成的影响.第四军医大学学报, 2004;25:1175-1178
93.张其胜,John M Luk,张健,田庚元.甘草次酸靶向肝星状细胞治疗肝纤维化的体内研究.中华肝脏病杂志,2005;13:664-667
94.康谊,王天才,梁扩寰.罗格列酮对四氯化碳诱导大鼠早期肝纤维化的抑制作用.华中科技大学学报(医学版),2006,35:81-83
95. Sugino H, Kumagai N, Watanabe S, Toda K, Takeuchi O, Tsunematsu S, Morinaga S, Tsuchimoto K. Polaprezinc attenuates liver fibrosis in a mouse model of non-alcoholic steatohepatitis. J Gastroenterol Hepatol. 2008 ;23:1909-1916
96. Ishigaki N, Yamamoto N, Jin H, Uchida K, Terai S, Sakaida I. Continuos intravenous infusion of atrial natriuretic peptide (ANP) prevented liver fibrosis in rat. Biochem Biophys Res Commun. 2009 ;378:354-359
97. Liu Y, Lui EL, Friedman SL, Li L, Ye T, Chen Y, Poon RT, Wo J, Kok TW, Fan ST. PTK787/ZK22258 attenuates stellate cell activation and hepatic fibrosis in vivo by inhibiting VEGF signaling. Lab Invest. 2009;89:209-221
98.马勇,丁体龙,袁福华,于莉,王莉,张文学.褪黑素对自身免疫性肝炎大鼠肝星状细胞透明质酸、Ⅲ型前胶原分泌及Ⅰ型胶原mRNA表达的抑制作用.肝脏,2008;13:235-237
99. Dutta J, Fan Y, Gupta N, Fan G, Gélinas C. Current insights into the regulation of programmed cell death by NF-kappaB. Oncogene, 2006, 25: 6800-6816
100.TergaonkarV. NF-κB pathway: a good signaling paradigm and therapeutic target. Int Biochem Cell Biol, 2006; 38 : 1647-1653
101.刘冰熔.核转录因子NF-κB─肿瘤基因治疗新焦点.国外医学免疫学分册,2001;24:129-132
102.Matsumoto H, Sato Y, Azumi J, Kato J, Niitsu Y, Tamaki K. Role of endotoxin in NF-kappaB activation by ethanol in rat hepatocytes. Alcohol Clin Exp Res. 2002 ; 26(8 Suppl): 6S-10S
103.Garg A, Aggawal BB. Nuclear transcription factor -κB as a target for cancer drug development. Leukemia. 2002, 16∶1053– 1068
104.Marpegan L, Bekinschtein TA, Freudenthal R, Rubio MF, Ferreyra GA, Romano A, Golombek DA. Participation of transcription factors from the Rel/NF-kappa B family in the circadian system in hamsters. Neurosci Lett. 2004 ;358:9-12
105.H?cker H, Karin M. Regulation and function of IKK and IKK-related kinases. Sci. STKE, 2006(357): re13
106.Matsuo S, Yamazaki S, Takeshige K, Muta T. Crucial roles of binding sites for NF-kappaB and C/EBPs in IkappaB-zeta-mediated transcriptional activation Biochem J. 2007 ;405:605-615
107.Chong LW, Hsu YC, Chiu YT, Yang KC, Huang YT. Anti-fibrotic effect of thalidomide on hepatic stellate cells and dimethylnitrosamine-intoxicated rats. J Biomed Sci., 2006, 13∶4 03– 418
108.Ahmed M E, Derek AM. Nuclear factor -κB and the Hepatic Inflammation- Fibrosisi– Cancer Axis. Hepatology, 2007; 46∶5 90– 597
109.Demirbilek S, Karaman A, Gürünlüo?lu K, Ta? E, Ak?n M, Aksoy RT, Türkmen E, Edal MN, Baykarabulut A. Polyenylphosphatidylcholine pretreatment protects rat liver from ischemia/reperfusion injury. Hepatol Res. 2006 ;34:84-91
110.Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by Glucocorticoids: Inhibition of NF-кB Activity Through Induction of I-кB Synthesis. Science, 1995; 270: 286-290
111.Liu SQ, Yu JP, Chen HL, Luo HS, Chen SM, Yu HG.. Therapeutic effects and molecular mechanisms of Ginkgo biloba extract on liver fibrosis in rats. Am J Chin Med. 2006;34:99-114
112.Cheng Y, Ping J, Xu LM. Effects of curcumin on peroxisome proliferator-activated receptor gamma expression and nuclear translocation/redistribution in culture- activated rat hepatic stellate cells. Chin Med J (Engl). 2007 ;120:794-801
113.Cressman DE, Greenbaum LE, Haber BA, Taub R. Rapid activation of post-hepatectomy factor/nuclear factor kappa B in hepatocytes, a primary response in the regenerating liver. J Biol Chem. 1994 ;269:30429-30435
114.Beraza N, Lüdde T, Assmus U, Roskams T, Vander Borght S, Trautwein C.Hepatocyte-specific IKK/NEMO expression determines the degree of liver injury. Gastroenterology, 2007, 132∶2 504– 2517
115.Geisler F, Algul H, Paxian S, Schmid R.M. Genetic inactivation of RelA / P65 sensitizes adult mouse hepatocytes to TNF - induced apoptosis in vivo and in vitro. Gastroenterology, 2007; 132∶2 489– 2503
116.尤红,王宝恩.核因子-кB在肝脏疾病中研究进展.临床肝胆杂志,2000;16:11-12
117.KarinM, Greten FR. NF - kappaB: linking inflammation and immunity to cancer development and progression . Nat Rew Immunol, 2005; 5∶749-759
118.Lv P, Luo HS, Zhou XP, Chireyath Paul S, Xiao YJ, Si XM, Liu SQ. Thalidomide prevents rat liver cirrhosis via inhibition of oxidative stress. Pathol Res Pract. 2006;202:777-788
119.Lv P, Luo HS, Zhou XP, Xiao YJ, Paul SC, Si XM, Zhou YH. Reversal effect of thalidomide on established hepatic cirrhosis in rats via inhibition of nuclear factor-kappaB/inhibitor of nuclear factor-kappaB pathway. Arch Med Res. 2007; 38:15-27
120.Nanji AA, Jokelainen K, Rahemtulla A, Miao L, Fogt F, Matsumoto H, Tahan SR, Su GL. Activation of nuclear factor kappa B and cytokine imbalance inexperimental alcoholic liver disease in the rat. Hepatology 1999;30:934-943
121.Nanji AA, Jokelainen K, Tipoe GL, Rahemtulla A, Dannenberg AJ. Dietary saturated fatty acids reverse inflammatory and fibrotic changes in rat liver despite continued ethanol administration. J Pharmacol Exp Ther. 2001;299:638-644
122.Nanji AA, Jokelainen K, Lau GK, Rahemtulla A, Tipoe GL, Polavarapu R, LalaniEN. Arginine reverses ethanol-induced inflammatory and fibrotic changes in liver despite continued ethanol administration. J Pharmacol Exp Ther. 2001;299:832-839
123.Ribeiro PS, Cortez-Pinto H, SoláS, Castro RE, Ramalho RM, Baptista A, Moura MC, Camilo ME, Rodrigues CM. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol. 2004 ;99:1708-1717
124.徐钧,解军,鲍民生,李正中,杨镇.核转录因子-кB在FK506保护肝脏缺血再灌注损伤中的作用.中华实验外科杂志, 2003; 20: 232-233
125.Rippe RA, Brenner DA. From quiescence to activation: Gene regulation in hepatic stellate cells. Gastroenterology. 2004 ;127:1260-1262
126.Hellerbrand C, Jobin C, Iimuro Y, Licato L, Sartor RB, Brenner DA. Inhibition of NFkappaB in activated rat hepatic stellate cells by proteasome inhibitors and an IkappaB super-repressor. Hepatology ,1998;27:1285-1295
127.Paik YH, Schwabe RF, Bataller R, Russo MP, Jobin C, Brenner DA.Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology ,2003; 37:1043-1055
128.Oakley F, Meso M, Iredale JP, Green K, Marek CJ, Zhou X, May MJ, Millward-Sadler H, Wright MC, Mann DA. Inhibition of inhibitor of kappaB kinases stimulates hepatic stellate cell apoptosis and accelerated recovery from rat liver fibrosis. Gastroenterology , 2005;128:108-120
129.Li X, Meng Y, Wu P, Zhang Z, Yang X. Angiotensin II and Aldosterone stimulating NF-kappaB and AP-1 activation in hepatic fibrosis of rat. Regul Pept. 2007; 138:15-25
130.Lee KS, Lee SJ, Park HJ, Chung JP, Han KH, Chon CY, Lee SI, Moon YM. Oxidative stress effect on the activation of hepatic stellate cells. Yonsei Med J. 2001; 42:1-8
131.Lee KS, Buck M, Houglum K, Chojkier M. Activation of hepatic stellate cells byTGF alpha and collagen type I is mediated by oxidative stress through c-myb expression. J Clin Invest 1995;96:2461-2468
132.Anan A, Baskin-Bey ES, Bronk SF, Werneburg NW, Shah VH, Gores GJ. Proteasome inhibition induces hepatic stellate cell apoptosis. Hepatology, 2006; 43:335-344
133.Lang A, Schoonhoven R, Tuvia S, Brenner DA, Rippe RA. Nuclear factor kappaB in proliferation, activation, and apoptosis in rat hepatic stellate cells. J Hepatol. 2000;33:49-58
134.Racanelli V, Rehermann B. The liver as an immunological organ. Hepatology ,2006; 43: S54-S62
135.Cao Q, Mak KM, Lieber CS. Dilinoleoylphosphatidylcholine decreases acetaldehyde-induced TNF-alpha generation in Kupffer cells of ethanol-fed rats. Biochem Biophys Res Commun. 2002 ;299:459-464
136.Shimohashi N, Nakamuta M, Uchimura K, Sugimoto R, Iwamoto H, Enjoji M, Nawata H. Selenoorganic compound, ebselen, inhibits nitric oxide and tumor necrosis factor-alpha production by the modulation of jun-N-terminal kinase and the NF-kappaB signaling pathway in rat Kupffer cells. J Cell Biochem. 2000;78:595-606
137.Anselmi K, Stolz DB, Nalesnik M, Watkins SC, Kamath R, Gandhi CR. Gliotoxin causes apoptosis and necrosis of rat Kupffer cells in vitro and in vivo in the absence of oxidative stress: exacerbation by caspase and serine protease inhibition. J Hepatol. 2007;47:103-113
138.刘玉平,许晏,甘子明,朱明,徐茜,顾丹今.小茴香对实验性肝纤维化大鼠细胞因子TNF-α的影响.新疆医科大学学报, 2008; 31:427-429
139.甄真,宋慧娟,李武军,赵彩彦,周俊英. NF-кB和TNF-α在暴发性肝衰竭肝组织中的表达及其意义.中国组织化学与细胞化学杂志, 2008; 17:45-49
140.刘庆生,王小奇,来立群,叶蔚,张洁,陈芝芸.三七对酒精性肝病大鼠肝组织学和TNF -α影响.中华中医药学刊, 2008; 26: 317-320
141..Essani NA, Fisher MA, Jaeschke H. Inhibition of NF-kappa B activation by dimethyl sulfoxide correlates with suppression of TNF-alpha formation, reduced ICAM-1 gene transcription, and protection against endotoxin-induced liver injury. Shock ,1997 ;7:90-96
142.Paul SC, Lv P, Xiao YJ, An P, Liu SQ, Luo HS. Thalidomide in rat liver cirrhosis: blockade of tumor necrosis factor-alpha via inhibition of degradation of an inhibitor of nuclear factor-kappaB. Pathobiology, 2006;73:82-92
143.Udalova IA, Kwiatkowski D. Interaction of AP-1 with a cluster of NF-kappa B binding elements in the human TNF promoter region. Biochem Biophys Res Commun, 2001; 289 : 25-33
144.Son EW, Mo SJ, Rhee DK, Pyo S. Inhibition of ICAM-1 expression by garlic component, allicin, in gamma-irradiated human vascular endothelial cells via downregulation of the JNK signaling pathway. Int Immunopharmacol. 2006; 6:1788-1795
145.刘新江. ICAM- 1 mRNA在大鼠缺血/再灌注肝脏组织中的表达.河南外科学杂志, 2007; 13: 1-2
146.Banga NR, Homer-Vanniasinkam S, Graham A, Al-Mukhtar A, White SA, Prasad KR. Ischaemic preconditioning in transplantation and major resection of the liver. Br J Surg 2005;92:528-538
147.Yokomori H, Oda M, Yoshimura K, Nomura M, Ogi M, Wakabayashi G, Kitajima M, Ishii H. Expression of intercellular adhesion molecule-1 and lymphocyte function-associated antigen-1 protein and messenger RNA in primary biliary cirrhosis. Intern Med. 2003 ;42: 947-954
148.Pata C, Yazar A, Altintas E, Polat G, Aydin O, Tiftik N, Konca K. Serum levels of intercellular adhesion molecule-1 and nitric oxide in patients with chronic hepatitis related to hepatitis C virus: connection fibrosis. Hepatogastroenterology, 2003;50:794-797
149.Girón-González JA, Martínez-Sierra C, Rodriguez-Ramos C, Rendón P, Macías MA, Fernández-Gutiérrez C, Díaz F, Martín-Herrera L. Adhesion molecules as a prognostic marker of liver cirrhosis. Scand J Gastroenterol. 2005 ;40:217-224
150.杨权,周军. ICAM- 1蛋白在慢性乙型肝炎肝衰竭肝组织中的表达.海南医学, 2008; 19: 21-22
151.张雪萍,刘新波,任永功,石碧明,李亚丽,姚尚龙,曾邦雄. NF-kappaB对ICAM-1表达的调节作用.中国临床药理学与治疗学,2006;11:55-58
152.Huang SH, Cao XJ, Wei W. Melatonin decreases TLR3-mediated inflammatory factor expression via inhibition of NF-kappa B activation in respiratory syncytial virus-infected RAW264.7 macrophage. J Pineal Res. 2008 ;45:93-100
153.Chetsawang B, Putthaprasart C, Phansuwan-Pujito P, Govitrapong P. Melatonin protects against hydrogen peroxide-induced cell death signaling in SH-SY5Y cultured cells: involvement of nuclear factor kappa B, Bax and Bcl-2. J Pineal Res. 2006 ;41:116-123
154.Alonso M, Collado PS, González-Gallego J. Melatonin inhibits the expression of the inducible isoform of nitric oxide synthase and nuclear factor kappa B activation in rat skeletal muscle. J Pineal Res. 2006 ;41:8-14
155.Li JH, Yu JP, Yu HG, Xu XM, Yu LL, Liu J, Luo HS. Melatonin reduces inflammatory injury through inhibiting NF-kappaB activation in rats with colitis. Mediators Inflamm. 2005 ;2005:185-193
156.Bruck R, Aeed H, Avni Y, Shirin H, Matas Z, Shahmurov M, Avinoach I, Zozulya G, Weizman N, Hochman A. Melatonin inhibits nuclear factor kappa B activation and oxidative stress and protects against thioacetamide induced liver damage in rats. J Hepatol. 2004 ;40:86-93
1. Sen R, Balt imore D. Mutiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell, 1986, 46: 705-716
2. Dutta J, Fan Y, Gupta N, Fan G, Gélinas C. Current insights into the regulation of programmed cell death by NF-kappaB. Oncogene, 2006, 25: 6800-6816
3. Liang Y, Zhou Y, Shen P. NF-kappaB and its regulation on the immune system. Cell Mol Immunol, 2004 ;1: 343-350
4. Gallagher NJ, Young LS. Nuclear factorкB in liver disease. Gut, 1999 ; 45:170-171
5. TergaonkarV. NF-κB pathway: a good signaling paradigm and therapeutic target. Int Biochem Cell Biol, 2006; 38 : 1647-1653
6. Hayden MS ,Ghosh S. Signaling to NF-кB .Genes Dev ,2004 ,18 :2195-2224
7. Takahashi Y, Ganster RW, Gambotto A, Shao L, Kaizu T, Wu T, Yagnik GP, Nakao A, Tsoulfas G, Ishikawa T, Okuda T, Geller DA, Murase N. Role of NFкB on liver cold ischemia-reperfusion injury. Am J Physiol Gastrointest Liver Physiol , 2002 ; 283: G1175-G1184
8.史艳晖,卢圣栋.转录因子NF-κB的研究现状及应用前景.中国生物工程杂志, 2007; 27 : 110–104
9. Baeuerle PA. IkappaB-NF-kappaB structures: at the interface of inflammation control. Cell, 1998 ; 95: 729-731
10. Bergqvist S, Croy CH, Kjaergaard M, Huxford T, Ghosh G, Komives EA. Thermodynamics reveal that helix four in the NLS of NF-kappaB p65 anchors IkappaBalpha, forming a very stable complex. J Mol Biol, 2006, 360 : 421-434
11. Sen CK, Packer L. Antioxidant and redox regulation of gene transcription. FASEB J,1996 ;10:709-720
12. Manna SK, Zhang HJ, Yan T, Oberley LW, Aggarwal BB. Overexpression of manganese superoxide dismutase suppresses tumor necrosis factor-inducedapoptosis and activation of nuclear transcription factor-kappaB and activated protein-1. J Biol Chem,1998 ;273:13245-13254
13. Meyer M, Schreck R, Baeuerle PA. H2O2 and antioxidants have opposite effects on activation of NF-kappa B and AP-1 in intact cells: AP-1 as secondary antioxidant-responsive factor. EMBO J,1993 ;12: 2005-2015
14.刘冰熔.核转录因子NF-κB─肿瘤基因治疗新焦点.国外医学免疫学分册,2001;24:129-132
15. Matsumoto H, Sato Y, Azumi J, Kato J, Niitsu Y, Tamaki K. Role of endotoxin in NF-kappaB activation by ethanol in rat hepatocytes. Alcohol Clin Exp Res, 2002 ; 26(8 Suppl): 6S-10S
16. Garg A, Aggawal BB. Nuclear transcription factor -κB as a target for cancer drug development. Leukemia, 2002; 16∶1 053– 1068
17. Marpegan L, Bekinschtein TA, Freudenthal R, Rubio MF, Ferreyra GA, Romano A, Golombek DA. Participation of transcrip tion factors from the Rel/NF-kappa B family in the circadian system in hamsters. Neurosci Lett, 2004 ;358:9-12
18. H?cker H, Karin M. Regulation and function of IKK and IKK-related kinases. Sci. STKE, 2006(357): re13
19. Matsuo S, Yamazaki S, Takeshige K, Muta T. Crucial roles of binding sites for NF-kappaB and C/EBPs in IkappaB-zeta-mediated transcriptional activation Biochem J, 2007 ;405:605-615
20. Chong LW, Hsu YC, Chiu YT, Yang KC, Huang YT. Anti-fibrotic effect of thalidomide on hepatic stellate cells and dimethylnitrosamine-intoxicated rats. J Biomed Sci, 2006, 13∶403– 418
21. Drew D, Shimada E, Huynh K, Bergqvist S, Talwar R, Karin M, Ghosh G.. Inhibitor kappaB kinase beta binding by inhibitor kappaB kinase gamma. Biochemistry, 2007 ; 46: 12482-12490
22. Chen FE, Ghosh G.. Regulation of DNA binding by Rel/NF-kappaB transcriptionfactors: structural views . Oncogene, 1999, 18 : 6845-6852
23. Luedde T,Trautwein C. Intracellular survival pathways in the liver.Liver Int, 2006 ; 26 :1163-1174
24. Schmid JA, Birbach A. IkappaB kinase beta (IKKbeta/IKK2/IKBKB)--a key molecule in signaling to the transcription factor NF-kappaB.Cytokine Growth Factor Rev, 2008, 19 : 157-165
25. Birbach A, Gold P, Binder BR, Hofer E, de Martin R, Schmid JA. Signaling molecules of the NF-kappa B pathway shuttle constitutively between cytoplasm and nucleus. J Boil Chem, 2002, 277 : 10842-10851
26. Ahmed M E, Derek AM. Nuclear factor-κB and the Hepatic Inflammation -Fibrosisi– Cancer Axis. Hepatology, 2007; 46∶590– 597
27. Videla LA, Tapia G, Rodrigo R, Pettinelli P, Haim D, Santiba?ez C, Araya AV, Smok G, Csendes A, Gutierrez L, Rojas J, Castillo J, Korn O, Maluenda F, Díaz JC, Rencoret G, Poniachik J. Liver NF-kappaB and AP-1 DNA binding in obese patients. Obesity (Silver Spring), 2009 ;17: 973-979
28. Domingo-Domènech J, Pippa R, Tápia M, Gascón P, Bachs O, Bosch M. Inactivation of NF-kappaB by proteasome inhibition contributes to increased apoptosis induced by histone deacetylase inhibitors in human breast cancer cells. Breast Cancer Res Treat, 2008 ;112: 53-62
29. Demirbilek S, Karaman A, Gürünlüo?lu K, Ta? E, Ak?n M, Aksoy RT, Türkmen E, Edal MN, Baykarabulut A. Polyenylphosphatidylcholine pretreatment protects rat liver from ischemia/reperfusion injury. Hepatol Res, 2006 ;34:84-91
30. Huang SH, Cao XJ, Wei W. Melatonin decreases TLR3-mediated inflammatory factor expression via inhibition of NF-kappa B activation in respiratory syncytial virus-infected RAW264.7 macrophage. J Pineal Res, 2008 ;45:93-100
31. Chetsawang B, Putthaprasart C, Phansuwan-Pujito P, Govitrapong P. Melatonin protects against hydrogen peroxide-induced cell death signaling in SH-SY5Ycultured cells: involvement of nuclear factor kappa B, Bax and Bcl-2. J Pineal Res, 2006 ;41:116-123
32. Alonso M, Collado PS, González-Gallego J. Melatonin inhibits the expression of the inducible isoform of nitric oxide synthase and nuclear factor kappa B activation in rat skeletal muscle. J Pineal Res, 2006 ;41:8-14
33. Li JH, Yu JP, Yu HG, Xu XM, Yu LL, Liu J, Luo HS. Melatonin reduces inflammatory injury through inhibiting NF-kappaB activation in rats with colitis. Mediators Inflamm, 2005 ;2005:185-193
34. Bruck R, Aeed H, Avni Y, Shirin H, Matas Z, Shahmurov M, Avinoach I, Zozulya G, Weizman N, Hochman A. Melatonin inhibits nuclear factor kappa B activation and oxidative stress and protects against thioacetamide induced liver damage in rats. J Hepatol,2004 ;40:86-93
35. Sepodes B, Maio R, Pinto R, Marques C, Mendes-do-Vale J, McDonald MC, Thiemermann C, Mota-Filipe H. Tempol, an intracelullar free radical scavenger, reduces liver injury in hepatic ischemia-reperfusion in the rat.Transplant Proc ,2004 ,36 :849-853
36. Traenckner EB, Wilk S, Baeuerle PA. A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B. EMBO J, 1994 ;13: 5433-5441
37. Kretz-Remy C, Mehlen P, Mirault ME, Arrigo AP. Inhibition of I kappa B-alpha phosphorylation and degradation and subsequent NF-kappa B activation by glutathione peroxidase overexpression. J Cell Biol, 1996 ;133: 1083-1093
38. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by Glucocorticoids: Inhibition of NF-кB Activity Through Induction of I-кB Synthesis. Science, 1995; 270: 286-290
39. Suetsugu H, Iimuro Y, Uehara T, Nishio T, Harada N, Yoshida M, Hatano E, Son G, Fujimoto J, Yamaoka Y. Nuclear factor {kappa}B inactivation in the rat liverameliorates short term total warm ischaemia-reperfusion injury. Gut ,2005 ,54 :835-842.
40. Xu MQ, Shuai XR, Yan ML, Zhang MM, Yan LN. Nuclear factor-kappaB decoy oligodeoxynucleotides attenuates ischemia/reperfusion injury in rat liver graft .World J Gastroenterol ,2005 ,11 :6960-6967
41. Virlos I, Mazzon E, Serraino I, Genovese T, Di Paola R, Thiemerman C, Siriwardena A, Cuzzocrea S. Calpain I inhibitor ameliorates the indices of disease severity in a murine model of cerulein-induced acute pancreatitis. Intensive Care Med, 2004 ;30:1645-1651
42. Liu SQ, Yu JP, Chen HL, Luo HS, Chen SM, Yu HG.. Therapeutic effects and molecular mechanisms of Ginkgo biloba extract on liver fibrosis in rats. Am J Chin Med, 2006;34:99-114
43. Cheng Y, Ping J, Xu LM. Effects of curcumin on peroxisome proliferator-activated receptor gamma expression and nuclear translocation/redistribution in culture-activated rat hepatic stellate cells. Chin Med J (Engl), 2007 ;120:794-801
44. Lang A, Brenner DA. Gene regulation in hepatic stellate cell. Ital J Gastroenterol Hepatol, 1999; 31:173-179
45. Rippe RA, Brenner DA. From quiescence to activation: Gene regulation in hepatic stellate cells. Gastroenterology, 2004 ;127:1260-1262
46. Lv P, Luo HS, Zhou XP, Xiao YJ, Paul SC, Si XM, Zhou YH. Reversal effect of thalidomide on established hepatic cirrhosis in rats via inhibition of nuclear factor-kappaB/inhibitor of nuclear factor-kappaB pathway. Arch Med Res, 2007 ;38:15-27
47. Hellerbrand C, Jobin C, Iimuro Y, Licato L, Sartor RB, Brenner DA. Inhibition of NFkappaB in activated rat hepatic stellate cells by proteasome inhibitors and an IkappaB super-repressor. Hepatology ,1998;27:1285-1295
48. Paik YH, Schwabe RF, Bataller R, Russo MP, Jobin C, Brenner DA.Toll-likereceptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology ,2003; 37:1043-1055
49. Oakley F, Meso M, Iredale JP, Green K, Marek CJ, Zhou X, May MJ, Millward-Sadler H, Wright MC, Mann DA. Inhibition of inhibitor of kappaB kinases stimulates hepatic stellate cell apoptosis and accelerated recovery from rat liver fibrosis. Gastroenterology , 2005;128:108-120
50. Li X, Meng Y, Wu P, Zhang Z, Yang X. Angiotensin II and Aldosterone stimulating NF-kappaB and AP-1 activation in hepatic fibrosis of rat. Regul Pept, 2007 ;138:15-25
51. Lee KS, Lee SJ, Park HJ, Chung JP, Han KH, Chon CY, Lee SI, Moon YM. Oxidative stress effect on the activation of hepatic stellate cells. Yonsei Med J, 2001 ;42:1-8
52. Lee KS, Buck M, Houglum K, Chojkier M. Activation of hepatic stellate cells by TGF alpha and collagen type I is mediated by oxidative stress through c-myb expression. J Clin Invest, 1995 ; 96: 2461-2468
53. Chaisson ML, Brooling JT, Ladiges W, Tsai S, Fausto N. Hepatocyte-specific inhibition of NF-kappaB leads to apoptosis after TNF treatment, but not after partial hepatectomy. J Clin Invest, 2002 ;110:193-202
54. Lang A, Schoonhoven R, Tuvia S, Brenner DA, Rippe RA. Nuclear factor kappaB in proliferation, activation, and apoptosis in rat hepatic stellate cells. J Hepatol, 2000 ;33: 49-58
55. Elsharkawy AM, Wright MC, Hay RT, Arthur MJ, Hughes T, Bahr MJ, Degitz K, Mann DA. Persistent activation of nuclear factor-kappaB in cultured rat hepatic stellate cells involves the induction of potentially novel Rel-like factors and prolonged changes in the expression of IkappaB family proteins. Hepatology, 1999 ; 30: 761-769
56. Anan A, Baskin-Bey ES, Bronk SF, Werneburg NW, Shah VH, Gores GJ.Proteasome inhibition induces hepatic stellate cell apoptosis. Hepatology, 2006 ;43:335-344
57. Racanelli V, Rehermann B. The liver as an immunological organ. Hepatology ,2006; 43: S54-S62
58. Fox ES, Cantrell CH, Leingang KA. Inhibition of the Kupffer cell inflammatory response by acute ethanol: NF-kappa B activation and subsequent cytokine production. Biochem Biophys Res Commun, 1996 ;225:134-140
59. Cao Q, Mak KM, Lieber CS. Dilinoleoylphosphatidylcholine decreases acetaldehyde-induced TNF-alpha generation in Kupffer cells of ethanol-fed rats. Biochem Biophys Res Commun, 2002 ;299:459-464
60. Shimohashi N, Nakamuta M, Uchimura K, Sugimoto R, Iwamoto H, Enjoji M, Nawata H. Selenoorganic compound, ebselen, inhibits nitric oxide and tumor necrosis factor-alpha production by the modulation of jun-N-terminal kinase and the NF-kappaB signaling pathway in rat Kupffer cells. J Cell Biochem, 2000 ;78:595-606
61. She H, Xiong S, Lin M, Zandi E, Giulivi C, Tsukamoto H. Iron activates NF-kappaB in Kupffer cells. Am J Physiol Gastrointest Liver Physiol., 2002 ; 283: G719-726
62. Anselmi K, Stolz DB, Nalesnik M, Watkins SC, Kamath R, Gandhi CR. Gliotoxin causes apoptosis and necrosis of rat Kupffer cells in vitro and in vivo in the absence of oxidative stress: exacerbation by caspase and serine protease inhibition. J Hepatol, 2007 ;47:103-113
63. Cressman DE, Greenbaum LE, Haber BA, Taub R. Rapid activation of post-hepatectomy factor/nuclear factor kappa B in hepatocytes, a primary response in the regenerating liver. J Biol Chem, 1994 ;269:30429-30435
64. Beraza N, Lüdde T, Assmus U, Roskams T, Vander Borght S, Trautwein C.Hepatocyte-specific IKK/NEMO expression determines the degree of liver injury.Gastroenterology, 2007, 132∶2 504– 2517
65. Geisler F, Algul H, Paxian S, Schmid R.M. Genetic inactivation of RelA / P65 sensitizes adult mouse hepatocytes to TNF - induced apoptosis in vivo and in vitro. Gastroenterology, 2007; 132∶2 489– 2503
66. Beg AA,Sha WC,Bronson RT,Ghosh S,Baltimore D. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature, 1995; 376: 167-170
67. Gallagher NJ, Young LS. Nuclear factor kappaB in liver disease. Gut,1999 ; 45:170-171
68. Kang KH, Lee KH, Kim MY, Choi KH. Caspase-3-mediated cleavage of the NF-kappa B subunit p65 at the NH2 terminus potentiates naphthoquinone analog-induced apoptosis. J Biol Chem. 2001 ;276:24638-24644
69. KarinM, Greten FR. NF - kappaB: linking inflammation and immunity to cancer development and progression . Nat Rew Immunol, 2005; 5∶749-759
70. Demoule A, Divangahi M, Yahiaoui L, Danialou G, Gvozdic D, Labbe K, Bao W, Petrof BJ. Endotoxin triggers nuclear factor-kappaB-dependent up-regulation of multiple proinflammatory genes in the diaphragm. Am J Respir Crit Care Med ,2006 ;174: 646-653
71. Liu SQ, Yu JP, Chen HL, Luo HS, Chen SM, Yu HG.. Therapeutic effects and molecular mechanisms of Ginkgo biloba extract on liver fibrosis in rats. Am J Chin Med, 2006;34:99-114
72. Lv P, Luo HS, Zhou XP, Chireyath Paul S, Xiao YJ, Si XM, Liu SQ. Thalidomide prevents rat liver cirrhosis via inhibition of oxidative stress. Pathol Res Pract, 2006;202:777-788
73. Lv P, Luo HS, Zhou XP, Xiao YJ, Paul SC, Si XM, Zhou YH. Reversal effect of thalidomide on established hepatic cirrhosis in rats via inhibition of nuclear factor-kappaB/inhibitor of nuclear factor-kappaB pathway. Arch Med Res,2007 ;38:15-27
74. Nanji AA, Jokelainen K, Rahemtulla A, Miao L, Fogt F, Matsumoto H, Tahan SR, Su GL. Activation of nuclear factor kappa B and cytokine imbalance inexperimental alcoholic liver disease in the rat. Hepatology, 1999;30:934-943
75. Nanji AA, Jokelainen K, Tipoe GL, Rahemtulla A, Dannenberg AJ. Dietary saturated fatty acids reverse inflammatory and fibrotic changes in rat liver despite continued ethanol administration. J Pharmacol Exp Ther, 2001;299:638-644
76. Nanji AA, Jokelainen K, Lau GK, Rahemtulla A, Tipoe GL, Polavarapu R, Lalani EN. Arginine reverses ethanol-induced inflammatory and fibrotic changes in liver despite continued ethanol administration. J Pharmacol Exp Ther, 2001;299:832-839
77. Ribeiro PS, Cortez-Pinto H, SoláS, Castro RE, Ramalho RM, Baptista A, Moura MC, Camilo ME, Rodrigues CM. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol, 2004 ;99:1708-1717
78. Zhong Z, Froh M, Connor HD, Li X, Conzelmann LO, Mason RP, Lemasters JJ, Thurman RG.. Prevention of hepatic ischemia-reperfusion injury by green tea extract. Am J Physiol Gastrointest Liver Physiol , 2002 ,283 :G957-G964
79. Okaya T, Lentsch AB. Hepatic expression of S32A/S36A I-κBαdoes not reduce postischemic liver injury. J Surg Res , 2005 ;124 :244-249
80. Luedde T, Assmus U, Wüstefeld T, Meyer zu Vilsendorf A, Roskams T, Schmidt-Supprian M, Rajewsky K, Brenner DA, Manns MP, Pasparakis M, Trautwein C. Deletion of IKK2 in hepatocytes does not sensitize these cells to TNF-induced apoptosis but protects from ischemia/reperfusion injury. J Clin Invest, 2005 ;115: 849-859
81. Xu J, Xie J, Bao M, Li Z, Yang Z. NF-kappaB/I-kappaB pathway during ischemia reperfusion injury of rat liver. Chin Med J (Engl),2003 ;116:1146-1149
82. Nüssler NC, Müller AR, Weidenbach H, Vergopoulos A, Platz KP, Volk HD,Neuhaus P, Nussler AK. IL-10 increases tissue injury after selective intestinal ischemia/reperfusion. Ann Surg ,2003 ,238 :49-58
83.徐钧,解军,鲍民生,李正中,杨镇.核转录因子-кB在FK506保护肝脏缺血再灌注损伤中的作用.中华实验外科杂志, 2003; 20: 232-233
84. Videla LA, Tapia G, Rodrigo R, Pettinelli P, Haim D, Santiba?ez C, Araya AV, Smok G, Csendes A, Gutierrez L, Rojas J, Castillo J, Korn O, Maluenda F, Díaz JC, Rencoret G, Poniachik J. Liver NF-kappaB and AP-1 DNA binding in obese patients. Obesity (Silver Spring) ,2009 ; 17: 973-979
85.陈芝芸,严茂祥,何蓓晖,刘庆生,孙丽伟.核转录因子кB在非酒精性脂肪肝大鼠肝组织中的表达.医学研究通讯, 2005;34:9-11
86.张爱忠,张赤志,许汉林,王汉敏.杞蓟制剂对非酒精性脂肪性肝炎大鼠肝组织核转录因子-κB / IκB的影响.实用肝脏病杂志, 2007; 10: 226-228
87. Guillermet-Guibert J, Saint-Laurent N, Davenne L, Rochaix P, Cuvillier O, Culler MD, Pradayrol L, Buscail L, Susini C, Bousquet C. Novel synergistic mechanism for sst2 somatostatin and TNFalpha receptors to induce apoptosis: crosstalk between NF-kappaB and JNK pathways. Cell Death Differ,2007 ;14: 197-208
88. Hagemann T, Wilson J, Kulbe H, Li NF, Leinster DA, Charles K, Klemm F, Pukrop T, Binder C, Balkwill FR. Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol, 2005 ;175:1197-1205
89. Bernal-Mizrachi L, Lovly CM, Ratner L. The role of NF-{kappa}B-1 and NF-{kappa}B-2-mediated resistance to apoptosis in lymphomas. Proc Natl Acad Sci U S A, 2006 ;103: 9220-9225
90. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature, 2006 ;441(7092):431-436
91. Lee KW, Kim MS, Kang NJ, Kim DH, Surh YJ, Lee HJ, Moon A. H-Ras selectively up-regulates MMP-9 and COX-2 through activation of ERK1/2 and NF-kappaB: an implication for invasive phenotype in rat liver epithelial cells. Int JCancer , 2006 ;119:1767-1775
92. Wang W, Luo HS, Yu BP. Exp ression of NF - kappaB and human telomerase reverse transcriptase in gastric cancer and precancerous lesions . World J Gastroenterol, 2004; 10 : 177 -181
93. Suh J, Rabson AB. NF-kappaB activation in human prostate cancer: important mediator or epiphenomenon? J Cell Biochem., 2004 ;9: 100-117
94. Qiao L, Zhang H, Yu J, Francisco R, Dent P, Ebert MP, R?cken C, Farrell G.. Constitutive activation of NF-kappaB in human hepatocellular carcinoma: evidence of a cytoprotective role. Hum Gene Ther, 2006 ;17: 280-290
95. Tai DI, Tsai SL, Chang YH, Huang SN, Chen TC, Chang KS, Liaw YF. Constitutive activation of nuclear factor kappaB in hepatocellular carcinoma. Cancer ,2000 ; 89: 2274-2281
96. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature, 2004 ; 431(7007): 461-466
97. Su XQ,Wu XH,Wu W. Kinetic alterations of liver nuclear factor-kappa B and TNF-αexpression at the early stage of HCC occurrence and clinical significances of their quantitative analysis . J Gastroenterol Hepatol,2006; 21(S2):A169
98. Wu JM, Sheng H, Saxena R, Skill NJ, Bhat-Nakshatri P, Yu M, Nakshatri H, Maluccio MA. NF-kappaB inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy. Cancer Lett, 2009 ; 278: 145-155
99. Sarkar FH,Li Y. NF-kappa B: A potential target for cancer chemoprevention and therap. Front Biosci, 2008; 13: 2950-2959
100.Elsharkawy AM, Mann DA. Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis. Hepatology , 2007 ; 46: 590-597
101.Thorgeirsson SS, Lee JS, Grisham JW. Functional genomics of hepatocellular carcinoma. Hepatology, 2006 ; 43(2 Suppl 1):S145-150
102.Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet, 2002 ; 31: 339-346
103.Lin A, Karin M. NF-kappaB in cancer: a marked target. Semin Cancer Biol. 2003 ; 13: 107-114.
104.Paur I, Austenaa LM, Blomhoff R. Extracts of dietary p lants are efficient modulators of nuclear factor kappa B . Food Chem Toxicol, 2008; 46 : 1288-1297
2. Lotersztajn S, Julien B, Teixeira-Clerc F, Grenard P, Mallat A. Hepatic fibrosis: molecular mechanisms and drug targets. Annu Rev Pharmacol Toxicol. 2005;45:605-28
3. Pinzani M. Therapies for hepatic fibrosis: real hope or just academic exercise? Dig Liver Dis. 2004;36:714-716
4. Mann DA, Smart DE. Transcriptional regulation of hepatic stellate cell activation. Gut, 2002; 50:891-896
5.尤红,王宝恩.核因子-кB在肝脏疾病中研究进展.临床肝胆杂志,2000;16:11-12
6. Aboutwerat A, Pemberton PW, Smith A, Burrows PC, McMahon RF, Jain SK, Warnes TW. Oxidant stress is a significant feature of primary biliary cirrhosis.Biochim Biophys Acta 2003;1637:142-150
7. Koruk M,Aksoy H,Akcay F,et al.Antioxidant capacity and nitric oxide in patients with hepatic cirrhosis.Ann Clin Lab Sci 2002;32:252-256.
8. Kitada T, Seki S, Iwai S, Yamada T, Sakaguchi H, Wakasa K. In situ detection of oxidative DNA damage, 8-hydroxydeoxyguanosine, in chronic human liver disease. J Hepatol. 2001;35: 613-618
9. Yang S, Tan TM, Wee A, Leow CK. Mitochondrial respiratory function and antioxidant capacity normal and cirrhosis livers following partial hepatectomy.Cell Mol Life Sci 2004;61:220-229.
10. Parola M,Robino G. Oxidative stress-related molecules and liver fibrosis.Journal of Hepatology, 2001;35:297-306.
11. Poli G.. Pathogenesis of liver fibrosis:role of oxidative stress.Molecular Aspects ofMedicine 2000;21:49-98.
12. Hernández-Mu?oz R, Díaz-Mu?oz M, Suárez-Cuenca JA, Trejo-Solís C, López V, Sánchez-Sevilla L, Yá?ez L, De Sánchez VC.Adenosine reverses a preestablished CCl4-induced micronodular cirrhosis through enhancing collagenolytic activity and stimulating hepatocyte cell proliferation in rats.Hepatology 2001;34:677-687.
13. Lieber CS, Leo MA, Cao Q, Ren C, DeCarli LM. Silymarin retards the progression of alcohol-induced hepatitis in baboons.J Clin Gastroenterol 2003;37:336-339.
14. Wasser S, Lim GY, Ong CN, Tan CE. Anti-oxidant ebselen causes the resolution of experimentally induced hepatic fibrosis in rats. J Gastroenterol Hepatol 2001;16:1244-1253.
15. Bruck R, Shirin H, Aeed H, Matas Z, Hochman A, Pines M, Avni Y. Prevention of hepatic cirrhosis in rats by hydroxyl radicals scavengers. J Hepatol 2001;35:457-464.
16. . Rozov SV, Filatova EV, Orlov AA, Volkova AV, Zhloba AR, Blashko EL, Pozdeyev NV. N1-acetyl-N2-formyl-5-methoxykynuramine is a product of melatonin oxidation in rats. J Pineal Res 2003; 35:245-250.
17. Sener-Murato?lu G, Paskalo?lu K, Arbak S, Hürda? C, Ayano?lu-Dülger G.. Protective effect of famotidine, omeprazole, and melatonin against acetylsalicylic acid-induced gastric damage in rats. Dig Dis Sci 2001; 46:318-330.
18. Tahan V, Ozaras R, Canbakan B, Uzun H, Aydin S, Yildirim B, Aytekin H, Ozbay G, Mert A, Senturk H. Melatonin reduces dimethylnitrosamine-induced liver fibrosis in rats. J Pineal Res 2004;37:78-84.
19. Ohta Y, Kongo-Nishimura M, Matsura T, Yamada K, Kitagawa A, Kishikawa T. Melatonin prevents disruption of hepatic reactive oxygen species metabolism in rats treated with carbon tetrachloride. J Pineal Res 2004; 36:10-17.
20. Chen JC, Ng CJ, Chiu TF, Chen HM. Altered neutrophil apoptosis activity is reversed by melatonin in liver ischemeia-reperfusion. J Pineal Res 2003;34:260-264.
21. Taysi S, Koc M, Büyükokuro?lu ME, Altinkaynak K, Sahin YN. Melatonin reduces lipid peroxidation and nitric oxide during irradiation induced oxidative injury in the rat liver. J Pineal Res 2003; 34:173-177.
22. Padillo FJ, Cruz A, Navarrete C, Bujalance I, Brice?o J, Gallardo JI, Marchal T, Caballero R, Túnez I, MuntanéJ, Montilla P, Pera-Madrazo C. Melatonin prevents oxidative stress and hepatocyte cell death induced by experimental cholestasis. Free Radic Res 2004; 38:697-704.
23. Zavodnik LB, Zavodnik IB, Lapshina EA, Belonovskaya EB, Martinchik DI, Kravchuk RI, Bryszewska M, Reiter RJ. Protective effects of melatonin against carbon tetrachloride hepatotoxicity in rats. Cell Biochemistry Function 2005;23:353-359.
24. Cruz A, Padillo FJ, Torres E, Navarrete CM, Mu?oz-Casta?eda JR, Caballero FJ, Brice?o J, Marchal T, Túnez I, Montilla P, Pera C, MuntanéJ.Melatonin prevents experiments liver cirrhosis induced by thioacetamide in rats.Journal of Pineal Research 2005; 39:143-150.
25. Tahan V, Ozaras R, Canbakan B, Uzun H, Aydin S, Yildirim B, Aytekin H, Ozbay G, Mert A, Senturk H. Melatonin reduces dimethylnitrosamine-induced liver fibrosis in rats. J Pineal Res 2004;37:78-84.
26. Natarajan M, Reiter RJ, Meltz ML, Herman TS. Effect of melatonin on cell growth, metabolic activity, and cell cycle distribution. J Pineal Res. 2001 ;31:228-233
27. Lezoualc'h F, Sparapani M, Behl C. N-acetyl-serotonin (normelatonin) and melatonin protect neurons against oxidative challenges and suppress the activity of the transcription factor NF-kappaB. J Pineal Res. 1998 ;24:168-178
28. Nava M, Quiroz Y, Vaziri N, Rodriguez-Iturbe B. Melatonin reduces renal interstitial inflammation and improves hypertension in spontaneously hypertensive rats. Am J Physiol Renal Physiol. 2003 ; 284:F447-454
29. Wang H, Wei W, Wang NP, Gui SY, Wu L, Sun WY, Xu SY. Melatonin ameliorates carbon tetrachloride-induced hepatic fibrogenesis in rats via inhibition of oxidative stress. Life Sci. 2005;77:1902-1915
30. Brenner DA. Signal transduction during liver regeneration. J Gastroenterol Hepatol. 1998 ;13 Suppl:S93-95
31. Zhang LJ, Yu JP, Li D, Huang YH, Chen ZX, Wang XZ. Effects of cytokines on carbon tetrachloride-induced hepatic fibrogenesis in rats. World J Gastroenterol. 2004;10:77-81
32. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13: 372-374
33. Wu J, Norton PA. Animal models of liver fibrosis. Scand J Gastroenterol 1996; 31: 1137-1143
34. Ohta Y, Kongo M, Sasaki E, Nishida K, Ishiguro I. Therapeutic effect of melatonin on carbon tetrachloride-induced acute liver injury in rats. J Pineal Res. 2000 ;28:119-126
35. Do?ru-Abbaso?lu S, Balkan J, Kanba?li O, Cevikba? U, Ayka?-Toker G, Uysal M. Aminoguanidine, an inducible nitric oxide synthase inhibitor, plus N-acetylcysteine treatment reduce the lipopolysaccharide-augmented hepatotoxicity in rats with cirrhosis . Hum Exp Toxicol 2002;21:359-364.
36. Vendemiale G, Grattagliano I, Caruso ML, Serviddio G, Valentini AM, Pirrelli M, Altomare E.. Increased oxidative sterss in dimethylnitrosamine-induced liver fibrosis in the rat:effect of N-acetylcysteine and interferon-alpha . Toxicol Appl Pharmacol, 2001; 175:130-139
37. Lee HJ, Oh YK, Rhee M, Lim JY, Hwang JY, Park YS, Kwon Y, Choi KH, Jo I, Park SI, Gao B, Kim WH. The role of STAT1/IRF-1 on synergistic ROS production and loss of mitochondrial transmembrane potential during hepatic cell death induced by LPS/d-GalN. J Mol Biol. 2007 ;369:967-984
38. Kim KY, Rhim T, Choi I, Kim SS. N-acetylcysteine induces cell cycle arrest in hepatic stellate cells through its reducing activity. J Biol Chem 2001; 276:40591-40598
39.乔玲,李亚明. N-乙酰半胱氨酸的作用机制和在肝病中的应用.医学综述,2007;13:39～40
40. Majano PL, Medina J, Zubía I, Sunyer L, Lara-Pezzi E, Maldonado-Rodríguez A, López-Cabrera M, Moreno-Otero R. N-Acetyl-cysteine modulates inducible nitric oxide synthase gene expression in human hepatocytes. J Hepatol. 2004 ;40:632-637
41. Zafarullah M, Li WQ, Sylvester J, Ahmad M. Molecular mechanisms of N-acetylcysteine actions. Cell Mol Life Sci. 2003 ;60:6-20
42. Serviddio G, Pereda J, PallardóFV, Carretero J, Borras C, Cutrin J, Vendemiale G, Poli G, Vi?a J, Sastre J. Ursodeoxycholic acid protects against secondary biliarycirrhosis in rats by preventing mitochondrial oxidative stress. Hepatology 2004; 39: 711-720
43. Lu G, Shimizu I, Cui X, Itonaga M, Tamaki K, Fukuno H, Inoue H, Honda H, Ito S. Antioxidant and antiapoptotic activities of idoxifene and estradiol in hepatic fibrosis in rats. Life Sci 2004; 74: 897-907
44. Geesin JC, Hendricks LJ, Falkenstein PA, Gordon JS, Berg RA. Regulation of collagen synthesis by ascorbic acid: characterization of the role of ascorbate-stimulated lipid peroxidation. Arch Biochem Biophys 1991; 290: 127-132
45. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115: 209-218
46. Gressner AM, Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med 2006; 10: 76-99
47. Brzezinski A. Melatonin in human. N Engl J Med 1997;336:186-195
48. Messner M, Huether G, Lorf T, Ramadori G, Schw?rer H. Presence of melatonin inthe human hepatobiliary-gastrointestinal tract. Life Sci. 2001 ;69:543-551
49. Cristina Tomás-Zapico, Ana Coto-Montes. Melatonin as antioxidant under pathological processes. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery 2007;1:63-82
50. Sener G, Jahovic N, Tosun O, Atasoy BM, Ye?en BC. Melatonin ameliorates ionizing radiation-induced oxidative organ damage in rats. : Life Sci. 2003 ;74:563-572
51. LB Zavodnik, IB Zavodnik, EA Lapshina, EB Belonovskaya, DI Martinchik, RI Kravchuk, M Bryszewska, RJ Reiter. Protective effects of melatonin against carbon tetrachloride hepatotoxicity in rats. Cell Biochemistry Function 2005;23:353-359
52. Liu F, Ng TB. Effect of pineal indoles on activities of the antioxidant defense enzymes superoxide dismutase, catalase, and glutathione reductase,and levels of reduced and oxidized glutathione in rat tissues. Biochem Cell Biol 2000;78:447-453
53.甄允方,孙庆林,顾志成,汪健.褪黑素对大鼠肝缺血再灌注损伤的保护作用.苏州大学学报(医学版),2007;27:41-42
54.周学武金国安罗春芬陈青江.褪黑素对大鼠肝缺血再灌注损伤的保护作用研究.浙江医学2006,28:642-644
55. El-Missiry MA, Fayed TA, El-Sawy MR, El-Sayed AA. Ameliorative effect of melatonin against gamma-irradiation-induced oxidative stress and tissue injury. Ecotoxicology and Environmental Safety 2007;66:278-86.
56. Montilla P, Cruz A, Padillo FJ, Túnez I, Gascon F, Mu?oz MC, Gómez M, Pera C. Melatonin versus vitamin E as protective treatment against oxidative stress after extra-hepatic bile duct ligation in rats. J Pineal Res. 2001 ;31:138-144
57. Ohta Y, Kongo M, Kishikawa T. Melatonin exerts a therapeutic effect on cholestatic liver injury in rats with bile duct ligation. J Pineal Res 2003;34:119-126
58. Padillo FJ, Cruz A, Navarrete C, Bujalance I, Brice?o J, Gallardo JI, Marchal T,Caballero R, Túnez I, MuntanéJ, Montilla P, Pera-Madrazo C. Melatonin prevents oxidative stress and hepatocyte cell death induced by experimental cholestasis. Free Radic Res 2004;38:697-704
59. Serviddio G, Pereda J, PallardóFV, Carretero J, Borras C, Cutrin J, Vendemiale G, Poli G, Vi?a J, Sastre J.Ursodeoxycholic acid protects against secondary biliary cirrhosis in rats by preventing mitochondrial oxidative stress. Hepatology 2004; 39: 711-720
60. El-Sokkary GH, Abdel-Rahman GH, Kamel ES. Melatonin protects against lead-induced hepatic and renal toxicity in male rats. Toxicology 2005;213:25-33.
61. Sigala F, Theocharis S, Sigalas K, Markantonis-Kyroudis S, Papalabros E, Triantafyllou A, Kostopanagiotou G, Andreadou I. Therapeutic value of melatonin in an experimental model of liver injury and regeneration. J Pineal Res 2006;40:270-279
62. Wang H, Xu DX, Lv JW, Ning H, Wei W. Melatonin attenuates lipopolysaccharide (LPS)-induced apoptotic liver damage in D-galactosamine-sensitized mice. Toxicology, 2007 ;237:49-57
63. Ostrowska Z, Swientochowska E, Buntner B, Marek B, Zwirska-Korczala K, Spyra Z, Banas I I. Assessment of relationship between secretion of melatonin,activity of thyroid, adrenal cortex as well as testes and chosen markers of collagen metabolism in starved rats. Endocrine Regulations 1996;30:83-92
64. Cunnane SC, Manku MS, Horrobin DF. The pineal and regulation of fibrosis: pinealectomy as a model of primary biliary cirrhosis: roles of melatonin and prostaglandins in fibrosis and regulation of T lymphocytes. Medical Hypotheses 1979; 5:403-414.
65.许建明,徐叔云,梅俏,丁长海,沈玉先.褪黑素对小鼠免疫性肝损伤的保护作用.中国药理学通报,1998;14:452-454
66.王华沈玉先魏伟董晨汪倪萍张玲玲岳莉.褪黑素对免疫性肝损伤小鼠自由基和细胞因子的影响.中国药理学通报2002;18:331-334
67.王映梅,李青,闫庆国,惠延平,马福成,胡沛臻.褪黑素对大鼠酒精性肝纤维化的作用.中国临床康复, 2006;10:74-76
68.刘卫辉,蔡川,周扬,刘芳娥,田少华.褪黑素对乙醇致小鼠慢性肝损伤的保护作用.第四军医大学学报,2006;27:1665-1667
69. Iba?ez P, Solis N, Pizarro M, Aguayo G, Duarte I, Miquel JF, Accatino L, Arrese M. Effect of losartan on early liver fibrosis development in a rat model of nonalcoholic steatohepatitis. J Gastroenterol Hepatol. 2007 ;22:846-851
70. Dang SS, Wang BF, Cheng YA, Song P, Liu ZG, Li ZF. Inhibitory effects of saikosaponin-d on CCl4-induced hepatic fibrogenesis in rats. World J Gastroenterol. 2007; 13: 557-563
71. Qiu JF, Zhang ZQ, Chen W, Wu ZY. Cystamine ameliorates liver fibrosis induced by carbon tetrachloride via inhibition of tissue transglutaminase. World J Gastroenterol 2007 ; 13: 4328-4332
72. Kaneda H, Hashimoto E, Yatsuji S, Tokushige K, Shiratori K. Hyaluronic acid levels can predict severe fibrosis and platelet counts can predict cirrhosis in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol 2006; 21: 1459-1465
73. Yin MF, Lian LH, Piao DM, Nan JX. Tetrandrine stimulates the apoptosis of hepatic stellate cells and ameliorates development of fibrosis in a thioacetamide rat model. World J Gastroenterol. 2007 ;13:1214-1220
74. Kaneda H, Hashimoto E, Yatsuji S, Tokushige K, Shiratori K. Hyaluronic acid levels can predict severe fibrosis and platelet counts can predict cirrhosis in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol. 2006;21:1459-1465.
75. Tamura T, Kobayashi H, Yamataka A, Lane GJ, Koga H, Miyano T. Inchin-ko-to prevents medium-term liver fibrosis in postoperative biliary atresia patients. Pediatr Surg Int. 2007;23:343-347
76. Suzuki A, Angulo P, Lymp J, Li D, Satomura S, Lindor K. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease. Liver Int. 2005;25:779-786
77. Li CH, Pan LH, Yang ZW, Li CY, Xu WX. Preventive effect of Qianggan-Rongxian Decoction on rat liver fibrosis. World J Gastroenterol. 2008;14:3569-3573
78. Fontana RJ, Goodman ZD, Dienstag JL, Bonkovsky HL, Naishadham D, Sterling RK, Su GL, Ghosh M, Wright EC; HALT-C Trial Group. Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology 2008 ;47:789-798
79. Khan JA, Khan FA, Dilawar M, Ijaz A, Khan NA, Mehmood T. Serum hyaluronic acid as a marker of hepatic. J Coll Physicians Surg Pak. 2007;17:323-326
80. He YT, Liu DW, Ding LY, Li Q, Xiao YH. Therapeutic effects and molecular mechanisms of anti-fibrosis herbs and selenium on rats with hepatic fibrosis. World J Gastroenterol. 2004 ;10:703-706
81. Wang H, Wei W, Wang NP, Wu CY, Yan SX, Yue L, Zhang LL, Xu SY. Effects of total glucosides of peony on immunological hepatic fibrosis in rats. World J Gastroenterol. 2005;11:2124-2129
82. Li CH, Piao DM, Xu WX, Yin ZR, Jin JS, Shen ZS. Morphological and serum hyaluronic acid, laminin and type IV collagen changes in dimethylnitrosamine- induced hepatic fibrosis of rats. World J Gastroenterol. 2005;11:7620-7624
83. Yang YY, Huang YT, Lee KC, Lee FY, Lee TY, Hou MC, Lin HC, Lee SD. Chronic administration of ursodeoxycholic acid decreases portal pressure in rats with biliary cirrhosis. Clin Sci (Lond). 2009 ;116:71-79
84. Koivisto H, Hietala J, Niemel? O. An inverse relationship between markers of fibrogenesis and collagen degradation in patients with or without alcoholic liver disease. Am J Gastroenterol. 2007;102:773-779
85. Trocme C, Leroy V, Sturm N, Hilleret MN, Bottari S, Morel F, Zarski JP.Longitudinal evaluation of a fibrosis index combining MMP-1 and PIIINP compared with MMP-9, TIMP-1 and hyaluronic acid in patients with chronic hepatitis C treated by interferon-alpha and ribavirin. J Viral Hepat. 2006; 13:643- 651
86. Kamal SM, Turner B, He Q, Rasenack J, Bianchi L, Al Tawil A, Nooman A, Massoud M, Koziel MJ, Afdhal NH. Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosis. Hepatology 2006;43:771-779
87. Drewa G, Krzyzyńska-Malinowska E, Wo?niak A, Protas-Drozd F, Mila-Kierzenkowska C, Rozwodowska M, Kowaliszyn B, Czajkowski R. Activity of superoxide dismutaseand and catalase and the level of lipid peroxidation products reactive with TBA in patients with psoriasis. Med Sci Monit 2002; 8: BR338-BR343
88. Ajamieh HH, Menéndez S, Martínez-Sánchez G, Candelario-Jalil E, Re L, Giuliani A, Fernández OS. Effects of ozone oxidative preconditioning on nitric oxide generation and cellular redox balance in a rat model of hepatic ischemia- reperfusion. Liver Int 2004; 24: 55-62
89. Shimizu I, Ma YR, Mizobuchi Y, Liu F, Miura T, Nakai Y, Yasuda M, Shiba M, Horie T, Amagaya S, Kawada N, Hori H, Ito S. Effect of Sho-saikoto, a Japanese herbal medicine, on hepatic fibrosis in rats. Hepatology 1999; 29:149-160
90. Zhou X, Murphy FR, Gehdu N, Zhang J, Iredale JP, Benyon RC.Engagement of aintegrin regulates proliferation and apoptosis of hepatic stellate cells.J Biol Chem,2004,279(23):23996-24006
91.王健,牛建昭,河福金,于世赢,白锦文,李或,赵丽云,赵福建,王继峰.脂多糖诱导大鼠肝星状细胞增殖与提高其胶原表达水平的细胞模型研究中西医结合肝病杂志2003;13:92-93
92.王卫卫,杨希山,李旭,王捷,田野,赖晃文,杨传红,赖日权.洛沙坦对肝纤维化大鼠AngⅡ1型受体的表达及胶原形成的影响.第四军医大学学报, 2004;25:1175-1178
93.张其胜,John M Luk,张健,田庚元.甘草次酸靶向肝星状细胞治疗肝纤维化的体内研究.中华肝脏病杂志,2005;13:664-667
94.康谊,王天才,梁扩寰.罗格列酮对四氯化碳诱导大鼠早期肝纤维化的抑制作用.华中科技大学学报(医学版),2006,35:81-83
95. Sugino H, Kumagai N, Watanabe S, Toda K, Takeuchi O, Tsunematsu S, Morinaga S, Tsuchimoto K. Polaprezinc attenuates liver fibrosis in a mouse model of non-alcoholic steatohepatitis. J Gastroenterol Hepatol. 2008 ;23:1909-1916
96. Ishigaki N, Yamamoto N, Jin H, Uchida K, Terai S, Sakaida I. Continuos intravenous infusion of atrial natriuretic peptide (ANP) prevented liver fibrosis in rat. Biochem Biophys Res Commun. 2009 ;378:354-359
97. Liu Y, Lui EL, Friedman SL, Li L, Ye T, Chen Y, Poon RT, Wo J, Kok TW, Fan ST. PTK787/ZK22258 attenuates stellate cell activation and hepatic fibrosis in vivo by inhibiting VEGF signaling. Lab Invest. 2009;89:209-221
98.马勇,丁体龙,袁福华,于莉,王莉,张文学.褪黑素对自身免疫性肝炎大鼠肝星状细胞透明质酸、Ⅲ型前胶原分泌及Ⅰ型胶原mRNA表达的抑制作用.肝脏,2008;13:235-237
99. Dutta J, Fan Y, Gupta N, Fan G, Gélinas C. Current insights into the regulation of programmed cell death by NF-kappaB. Oncogene, 2006, 25: 6800-6816
100.TergaonkarV. NF-κB pathway: a good signaling paradigm and therapeutic target. Int Biochem Cell Biol, 2006; 38 : 1647-1653
101.刘冰熔.核转录因子NF-κB─肿瘤基因治疗新焦点.国外医学免疫学分册,2001;24:129-132
102.Matsumoto H, Sato Y, Azumi J, Kato J, Niitsu Y, Tamaki K. Role of endotoxin in NF-kappaB activation by ethanol in rat hepatocytes. Alcohol Clin Exp Res. 2002 ; 26(8 Suppl): 6S-10S
103.Garg A, Aggawal BB. Nuclear transcription factor -κB as a target for cancer drug development. Leukemia. 2002, 16∶1053– 1068
104.Marpegan L, Bekinschtein TA, Freudenthal R, Rubio MF, Ferreyra GA, Romano A, Golombek DA. Participation of transcription factors from the Rel/NF-kappa B family in the circadian system in hamsters. Neurosci Lett. 2004 ;358:9-12
105.H?cker H, Karin M. Regulation and function of IKK and IKK-related kinases. Sci. STKE, 2006(357): re13
106.Matsuo S, Yamazaki S, Takeshige K, Muta T. Crucial roles of binding sites for NF-kappaB and C/EBPs in IkappaB-zeta-mediated transcriptional activation Biochem J. 2007 ;405:605-615
107.Chong LW, Hsu YC, Chiu YT, Yang KC, Huang YT. Anti-fibrotic effect of thalidomide on hepatic stellate cells and dimethylnitrosamine-intoxicated rats. J Biomed Sci., 2006, 13∶4 03– 418
108.Ahmed M E, Derek AM. Nuclear factor -κB and the Hepatic Inflammation- Fibrosisi– Cancer Axis. Hepatology, 2007; 46∶5 90– 597
109.Demirbilek S, Karaman A, Gürünlüo?lu K, Ta? E, Ak?n M, Aksoy RT, Türkmen E, Edal MN, Baykarabulut A. Polyenylphosphatidylcholine pretreatment protects rat liver from ischemia/reperfusion injury. Hepatol Res. 2006 ;34:84-91
110.Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by Glucocorticoids: Inhibition of NF-кB Activity Through Induction of I-кB Synthesis. Science, 1995; 270: 286-290
111.Liu SQ, Yu JP, Chen HL, Luo HS, Chen SM, Yu HG.. Therapeutic effects and molecular mechanisms of Ginkgo biloba extract on liver fibrosis in rats. Am J Chin Med. 2006;34:99-114
112.Cheng Y, Ping J, Xu LM. Effects of curcumin on peroxisome proliferator-activated receptor gamma expression and nuclear translocation/redistribution in culture- activated rat hepatic stellate cells. Chin Med J (Engl). 2007 ;120:794-801
113.Cressman DE, Greenbaum LE, Haber BA, Taub R. Rapid activation of post-hepatectomy factor/nuclear factor kappa B in hepatocytes, a primary response in the regenerating liver. J Biol Chem. 1994 ;269:30429-30435
114.Beraza N, Lüdde T, Assmus U, Roskams T, Vander Borght S, Trautwein C.Hepatocyte-specific IKK/NEMO expression determines the degree of liver injury. Gastroenterology, 2007, 132∶2 504– 2517
115.Geisler F, Algul H, Paxian S, Schmid R.M. Genetic inactivation of RelA / P65 sensitizes adult mouse hepatocytes to TNF - induced apoptosis in vivo and in vitro. Gastroenterology, 2007; 132∶2 489– 2503
116.尤红,王宝恩.核因子-кB在肝脏疾病中研究进展.临床肝胆杂志,2000;16:11-12
117.KarinM, Greten FR. NF - kappaB: linking inflammation and immunity to cancer development and progression . Nat Rew Immunol, 2005; 5∶749-759
118.Lv P, Luo HS, Zhou XP, Chireyath Paul S, Xiao YJ, Si XM, Liu SQ. Thalidomide prevents rat liver cirrhosis via inhibition of oxidative stress. Pathol Res Pract. 2006;202:777-788
119.Lv P, Luo HS, Zhou XP, Xiao YJ, Paul SC, Si XM, Zhou YH. Reversal effect of thalidomide on established hepatic cirrhosis in rats via inhibition of nuclear factor-kappaB/inhibitor of nuclear factor-kappaB pathway. Arch Med Res. 2007; 38:15-27
120.Nanji AA, Jokelainen K, Rahemtulla A, Miao L, Fogt F, Matsumoto H, Tahan SR, Su GL. Activation of nuclear factor kappa B and cytokine imbalance inexperimental alcoholic liver disease in the rat. Hepatology 1999;30:934-943
121.Nanji AA, Jokelainen K, Tipoe GL, Rahemtulla A, Dannenberg AJ. Dietary saturated fatty acids reverse inflammatory and fibrotic changes in rat liver despite continued ethanol administration. J Pharmacol Exp Ther. 2001;299:638-644
122.Nanji AA, Jokelainen K, Lau GK, Rahemtulla A, Tipoe GL, Polavarapu R, LalaniEN. Arginine reverses ethanol-induced inflammatory and fibrotic changes in liver despite continued ethanol administration. J Pharmacol Exp Ther. 2001;299:832-839
123.Ribeiro PS, Cortez-Pinto H, SoláS, Castro RE, Ramalho RM, Baptista A, Moura MC, Camilo ME, Rodrigues CM. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol. 2004 ;99:1708-1717
124.徐钧,解军,鲍民生,李正中,杨镇.核转录因子-кB在FK506保护肝脏缺血再灌注损伤中的作用.中华实验外科杂志, 2003; 20: 232-233
125.Rippe RA, Brenner DA. From quiescence to activation: Gene regulation in hepatic stellate cells. Gastroenterology. 2004 ;127:1260-1262
126.Hellerbrand C, Jobin C, Iimuro Y, Licato L, Sartor RB, Brenner DA. Inhibition of NFkappaB in activated rat hepatic stellate cells by proteasome inhibitors and an IkappaB super-repressor. Hepatology ,1998;27:1285-1295
127.Paik YH, Schwabe RF, Bataller R, Russo MP, Jobin C, Brenner DA.Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology ,2003; 37:1043-1055
128.Oakley F, Meso M, Iredale JP, Green K, Marek CJ, Zhou X, May MJ, Millward-Sadler H, Wright MC, Mann DA. Inhibition of inhibitor of kappaB kinases stimulates hepatic stellate cell apoptosis and accelerated recovery from rat liver fibrosis. Gastroenterology , 2005;128:108-120
129.Li X, Meng Y, Wu P, Zhang Z, Yang X. Angiotensin II and Aldosterone stimulating NF-kappaB and AP-1 activation in hepatic fibrosis of rat. Regul Pept. 2007; 138:15-25
130.Lee KS, Lee SJ, Park HJ, Chung JP, Han KH, Chon CY, Lee SI, Moon YM. Oxidative stress effect on the activation of hepatic stellate cells. Yonsei Med J. 2001; 42:1-8
131.Lee KS, Buck M, Houglum K, Chojkier M. Activation of hepatic stellate cells byTGF alpha and collagen type I is mediated by oxidative stress through c-myb expression. J Clin Invest 1995;96:2461-2468
132.Anan A, Baskin-Bey ES, Bronk SF, Werneburg NW, Shah VH, Gores GJ. Proteasome inhibition induces hepatic stellate cell apoptosis. Hepatology, 2006; 43:335-344
133.Lang A, Schoonhoven R, Tuvia S, Brenner DA, Rippe RA. Nuclear factor kappaB in proliferation, activation, and apoptosis in rat hepatic stellate cells. J Hepatol. 2000;33:49-58
134.Racanelli V, Rehermann B. The liver as an immunological organ. Hepatology ,2006; 43: S54-S62
135.Cao Q, Mak KM, Lieber CS. Dilinoleoylphosphatidylcholine decreases acetaldehyde-induced TNF-alpha generation in Kupffer cells of ethanol-fed rats. Biochem Biophys Res Commun. 2002 ;299:459-464
136.Shimohashi N, Nakamuta M, Uchimura K, Sugimoto R, Iwamoto H, Enjoji M, Nawata H. Selenoorganic compound, ebselen, inhibits nitric oxide and tumor necrosis factor-alpha production by the modulation of jun-N-terminal kinase and the NF-kappaB signaling pathway in rat Kupffer cells. J Cell Biochem. 2000;78:595-606
137.Anselmi K, Stolz DB, Nalesnik M, Watkins SC, Kamath R, Gandhi CR. Gliotoxin causes apoptosis and necrosis of rat Kupffer cells in vitro and in vivo in the absence of oxidative stress: exacerbation by caspase and serine protease inhibition. J Hepatol. 2007;47:103-113
138.刘玉平,许晏,甘子明,朱明,徐茜,顾丹今.小茴香对实验性肝纤维化大鼠细胞因子TNF-α的影响.新疆医科大学学报, 2008; 31:427-429
139.甄真,宋慧娟,李武军,赵彩彦,周俊英. NF-кB和TNF-α在暴发性肝衰竭肝组织中的表达及其意义.中国组织化学与细胞化学杂志, 2008; 17:45-49
140.刘庆生,王小奇,来立群,叶蔚,张洁,陈芝芸.三七对酒精性肝病大鼠肝组织学和TNF -α影响.中华中医药学刊, 2008; 26: 317-320
141..Essani NA, Fisher MA, Jaeschke H. Inhibition of NF-kappa B activation by dimethyl sulfoxide correlates with suppression of TNF-alpha formation, reduced ICAM-1 gene transcription, and protection against endotoxin-induced liver injury. Shock ,1997 ;7:90-96
142.Paul SC, Lv P, Xiao YJ, An P, Liu SQ, Luo HS. Thalidomide in rat liver cirrhosis: blockade of tumor necrosis factor-alpha via inhibition of degradation of an inhibitor of nuclear factor-kappaB. Pathobiology, 2006;73:82-92
143.Udalova IA, Kwiatkowski D. Interaction of AP-1 with a cluster of NF-kappa B binding elements in the human TNF promoter region. Biochem Biophys Res Commun, 2001; 289 : 25-33
144.Son EW, Mo SJ, Rhee DK, Pyo S. Inhibition of ICAM-1 expression by garlic component, allicin, in gamma-irradiated human vascular endothelial cells via downregulation of the JNK signaling pathway. Int Immunopharmacol. 2006; 6:1788-1795
145.刘新江. ICAM- 1 mRNA在大鼠缺血/再灌注肝脏组织中的表达.河南外科学杂志, 2007; 13: 1-2
146.Banga NR, Homer-Vanniasinkam S, Graham A, Al-Mukhtar A, White SA, Prasad KR. Ischaemic preconditioning in transplantation and major resection of the liver. Br J Surg 2005;92:528-538
147.Yokomori H, Oda M, Yoshimura K, Nomura M, Ogi M, Wakabayashi G, Kitajima M, Ishii H. Expression of intercellular adhesion molecule-1 and lymphocyte function-associated antigen-1 protein and messenger RNA in primary biliary cirrhosis. Intern Med. 2003 ;42: 947-954
148.Pata C, Yazar A, Altintas E, Polat G, Aydin O, Tiftik N, Konca K. Serum levels of intercellular adhesion molecule-1 and nitric oxide in patients with chronic hepatitis related to hepatitis C virus: connection fibrosis. Hepatogastroenterology, 2003;50:794-797
149.Girón-González JA, Martínez-Sierra C, Rodriguez-Ramos C, Rendón P, Macías MA, Fernández-Gutiérrez C, Díaz F, Martín-Herrera L. Adhesion molecules as a prognostic marker of liver cirrhosis. Scand J Gastroenterol. 2005 ;40:217-224
150.杨权,周军. ICAM- 1蛋白在慢性乙型肝炎肝衰竭肝组织中的表达.海南医学, 2008; 19: 21-22
151.张雪萍,刘新波,任永功,石碧明,李亚丽,姚尚龙,曾邦雄. NF-kappaB对ICAM-1表达的调节作用.中国临床药理学与治疗学,2006;11:55-58
152.Huang SH, Cao XJ, Wei W. Melatonin decreases TLR3-mediated inflammatory factor expression via inhibition of NF-kappa B activation in respiratory syncytial virus-infected RAW264.7 macrophage. J Pineal Res. 2008 ;45:93-100
153.Chetsawang B, Putthaprasart C, Phansuwan-Pujito P, Govitrapong P. Melatonin protects against hydrogen peroxide-induced cell death signaling in SH-SY5Y cultured cells: involvement of nuclear factor kappa B, Bax and Bcl-2. J Pineal Res. 2006 ;41:116-123
154.Alonso M, Collado PS, González-Gallego J. Melatonin inhibits the expression of the inducible isoform of nitric oxide synthase and nuclear factor kappa B activation in rat skeletal muscle. J Pineal Res. 2006 ;41:8-14
155.Li JH, Yu JP, Yu HG, Xu XM, Yu LL, Liu J, Luo HS. Melatonin reduces inflammatory injury through inhibiting NF-kappaB activation in rats with colitis. Mediators Inflamm. 2005 ;2005:185-193
156.Bruck R, Aeed H, Avni Y, Shirin H, Matas Z, Shahmurov M, Avinoach I, Zozulya G, Weizman N, Hochman A. Melatonin inhibits nuclear factor kappa B activation and oxidative stress and protects against thioacetamide induced liver damage in rats. J Hepatol. 2004 ;40:86-93
1. Sen R, Balt imore D. Mutiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell, 1986, 46: 705-716
2. Dutta J, Fan Y, Gupta N, Fan G, Gélinas C. Current insights into the regulation of programmed cell death by NF-kappaB. Oncogene, 2006, 25: 6800-6816
3. Liang Y, Zhou Y, Shen P. NF-kappaB and its regulation on the immune system. Cell Mol Immunol, 2004 ;1: 343-350
4. Gallagher NJ, Young LS. Nuclear factorкB in liver disease. Gut, 1999 ; 45:170-171
5. TergaonkarV. NF-κB pathway: a good signaling paradigm and therapeutic target. Int Biochem Cell Biol, 2006; 38 : 1647-1653
6. Hayden MS ,Ghosh S. Signaling to NF-кB .Genes Dev ,2004 ,18 :2195-2224
7. Takahashi Y, Ganster RW, Gambotto A, Shao L, Kaizu T, Wu T, Yagnik GP, Nakao A, Tsoulfas G, Ishikawa T, Okuda T, Geller DA, Murase N. Role of NFкB on liver cold ischemia-reperfusion injury. Am J Physiol Gastrointest Liver Physiol , 2002 ; 283: G1175-G1184
8.史艳晖,卢圣栋.转录因子NF-κB的研究现状及应用前景.中国生物工程杂志, 2007; 27 : 110–104
9. Baeuerle PA. IkappaB-NF-kappaB structures: at the interface of inflammation control. Cell, 1998 ; 95: 729-731
10. Bergqvist S, Croy CH, Kjaergaard M, Huxford T, Ghosh G, Komives EA. Thermodynamics reveal that helix four in the NLS of NF-kappaB p65 anchors IkappaBalpha, forming a very stable complex. J Mol Biol, 2006, 360 : 421-434
11. Sen CK, Packer L. Antioxidant and redox regulation of gene transcription. FASEB J,1996 ;10:709-720
12. Manna SK, Zhang HJ, Yan T, Oberley LW, Aggarwal BB. Overexpression of manganese superoxide dismutase suppresses tumor necrosis factor-inducedapoptosis and activation of nuclear transcription factor-kappaB and activated protein-1. J Biol Chem,1998 ;273:13245-13254
13. Meyer M, Schreck R, Baeuerle PA. H2O2 and antioxidants have opposite effects on activation of NF-kappa B and AP-1 in intact cells: AP-1 as secondary antioxidant-responsive factor. EMBO J,1993 ;12: 2005-2015
14.刘冰熔.核转录因子NF-κB─肿瘤基因治疗新焦点.国外医学免疫学分册,2001;24:129-132
15. Matsumoto H, Sato Y, Azumi J, Kato J, Niitsu Y, Tamaki K. Role of endotoxin in NF-kappaB activation by ethanol in rat hepatocytes. Alcohol Clin Exp Res, 2002 ; 26(8 Suppl): 6S-10S
16. Garg A, Aggawal BB. Nuclear transcription factor -κB as a target for cancer drug development. Leukemia, 2002; 16∶1 053– 1068
17. Marpegan L, Bekinschtein TA, Freudenthal R, Rubio MF, Ferreyra GA, Romano A, Golombek DA. Participation of transcrip tion factors from the Rel/NF-kappa B family in the circadian system in hamsters. Neurosci Lett, 2004 ;358:9-12
18. H?cker H, Karin M. Regulation and function of IKK and IKK-related kinases. Sci. STKE, 2006(357): re13
19. Matsuo S, Yamazaki S, Takeshige K, Muta T. Crucial roles of binding sites for NF-kappaB and C/EBPs in IkappaB-zeta-mediated transcriptional activation Biochem J, 2007 ;405:605-615
20. Chong LW, Hsu YC, Chiu YT, Yang KC, Huang YT. Anti-fibrotic effect of thalidomide on hepatic stellate cells and dimethylnitrosamine-intoxicated rats. J Biomed Sci, 2006, 13∶403– 418
21. Drew D, Shimada E, Huynh K, Bergqvist S, Talwar R, Karin M, Ghosh G.. Inhibitor kappaB kinase beta binding by inhibitor kappaB kinase gamma. Biochemistry, 2007 ; 46: 12482-12490
22. Chen FE, Ghosh G.. Regulation of DNA binding by Rel/NF-kappaB transcriptionfactors: structural views . Oncogene, 1999, 18 : 6845-6852
23. Luedde T,Trautwein C. Intracellular survival pathways in the liver.Liver Int, 2006 ; 26 :1163-1174
24. Schmid JA, Birbach A. IkappaB kinase beta (IKKbeta/IKK2/IKBKB)--a key molecule in signaling to the transcription factor NF-kappaB.Cytokine Growth Factor Rev, 2008, 19 : 157-165
25. Birbach A, Gold P, Binder BR, Hofer E, de Martin R, Schmid JA. Signaling molecules of the NF-kappa B pathway shuttle constitutively between cytoplasm and nucleus. J Boil Chem, 2002, 277 : 10842-10851
26. Ahmed M E, Derek AM. Nuclear factor-κB and the Hepatic Inflammation -Fibrosisi– Cancer Axis. Hepatology, 2007; 46∶590– 597
27. Videla LA, Tapia G, Rodrigo R, Pettinelli P, Haim D, Santiba?ez C, Araya AV, Smok G, Csendes A, Gutierrez L, Rojas J, Castillo J, Korn O, Maluenda F, Díaz JC, Rencoret G, Poniachik J. Liver NF-kappaB and AP-1 DNA binding in obese patients. Obesity (Silver Spring), 2009 ;17: 973-979
28. Domingo-Domènech J, Pippa R, Tápia M, Gascón P, Bachs O, Bosch M. Inactivation of NF-kappaB by proteasome inhibition contributes to increased apoptosis induced by histone deacetylase inhibitors in human breast cancer cells. Breast Cancer Res Treat, 2008 ;112: 53-62
29. Demirbilek S, Karaman A, Gürünlüo?lu K, Ta? E, Ak?n M, Aksoy RT, Türkmen E, Edal MN, Baykarabulut A. Polyenylphosphatidylcholine pretreatment protects rat liver from ischemia/reperfusion injury. Hepatol Res, 2006 ;34:84-91
30. Huang SH, Cao XJ, Wei W. Melatonin decreases TLR3-mediated inflammatory factor expression via inhibition of NF-kappa B activation in respiratory syncytial virus-infected RAW264.7 macrophage. J Pineal Res, 2008 ;45:93-100
31. Chetsawang B, Putthaprasart C, Phansuwan-Pujito P, Govitrapong P. Melatonin protects against hydrogen peroxide-induced cell death signaling in SH-SY5Ycultured cells: involvement of nuclear factor kappa B, Bax and Bcl-2. J Pineal Res, 2006 ;41:116-123
32. Alonso M, Collado PS, González-Gallego J. Melatonin inhibits the expression of the inducible isoform of nitric oxide synthase and nuclear factor kappa B activation in rat skeletal muscle. J Pineal Res, 2006 ;41:8-14
33. Li JH, Yu JP, Yu HG, Xu XM, Yu LL, Liu J, Luo HS. Melatonin reduces inflammatory injury through inhibiting NF-kappaB activation in rats with colitis. Mediators Inflamm, 2005 ;2005:185-193
34. Bruck R, Aeed H, Avni Y, Shirin H, Matas Z, Shahmurov M, Avinoach I, Zozulya G, Weizman N, Hochman A. Melatonin inhibits nuclear factor kappa B activation and oxidative stress and protects against thioacetamide induced liver damage in rats. J Hepatol,2004 ;40:86-93
35. Sepodes B, Maio R, Pinto R, Marques C, Mendes-do-Vale J, McDonald MC, Thiemermann C, Mota-Filipe H. Tempol, an intracelullar free radical scavenger, reduces liver injury in hepatic ischemia-reperfusion in the rat.Transplant Proc ,2004 ,36 :849-853
36. Traenckner EB, Wilk S, Baeuerle PA. A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B. EMBO J, 1994 ;13: 5433-5441
37. Kretz-Remy C, Mehlen P, Mirault ME, Arrigo AP. Inhibition of I kappa B-alpha phosphorylation and degradation and subsequent NF-kappa B activation by glutathione peroxidase overexpression. J Cell Biol, 1996 ;133: 1083-1093
38. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by Glucocorticoids: Inhibition of NF-кB Activity Through Induction of I-кB Synthesis. Science, 1995; 270: 286-290
39. Suetsugu H, Iimuro Y, Uehara T, Nishio T, Harada N, Yoshida M, Hatano E, Son G, Fujimoto J, Yamaoka Y. Nuclear factor {kappa}B inactivation in the rat liverameliorates short term total warm ischaemia-reperfusion injury. Gut ,2005 ,54 :835-842.
40. Xu MQ, Shuai XR, Yan ML, Zhang MM, Yan LN. Nuclear factor-kappaB decoy oligodeoxynucleotides attenuates ischemia/reperfusion injury in rat liver graft .World J Gastroenterol ,2005 ,11 :6960-6967
41. Virlos I, Mazzon E, Serraino I, Genovese T, Di Paola R, Thiemerman C, Siriwardena A, Cuzzocrea S. Calpain I inhibitor ameliorates the indices of disease severity in a murine model of cerulein-induced acute pancreatitis. Intensive Care Med, 2004 ;30:1645-1651
42. Liu SQ, Yu JP, Chen HL, Luo HS, Chen SM, Yu HG.. Therapeutic effects and molecular mechanisms of Ginkgo biloba extract on liver fibrosis in rats. Am J Chin Med, 2006;34:99-114
43. Cheng Y, Ping J, Xu LM. Effects of curcumin on peroxisome proliferator-activated receptor gamma expression and nuclear translocation/redistribution in culture-activated rat hepatic stellate cells. Chin Med J (Engl), 2007 ;120:794-801
44. Lang A, Brenner DA. Gene regulation in hepatic stellate cell. Ital J Gastroenterol Hepatol, 1999; 31:173-179
45. Rippe RA, Brenner DA. From quiescence to activation: Gene regulation in hepatic stellate cells. Gastroenterology, 2004 ;127:1260-1262
46. Lv P, Luo HS, Zhou XP, Xiao YJ, Paul SC, Si XM, Zhou YH. Reversal effect of thalidomide on established hepatic cirrhosis in rats via inhibition of nuclear factor-kappaB/inhibitor of nuclear factor-kappaB pathway. Arch Med Res, 2007 ;38:15-27
47. Hellerbrand C, Jobin C, Iimuro Y, Licato L, Sartor RB, Brenner DA. Inhibition of NFkappaB in activated rat hepatic stellate cells by proteasome inhibitors and an IkappaB super-repressor. Hepatology ,1998;27:1285-1295
48. Paik YH, Schwabe RF, Bataller R, Russo MP, Jobin C, Brenner DA.Toll-likereceptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology ,2003; 37:1043-1055
49. Oakley F, Meso M, Iredale JP, Green K, Marek CJ, Zhou X, May MJ, Millward-Sadler H, Wright MC, Mann DA. Inhibition of inhibitor of kappaB kinases stimulates hepatic stellate cell apoptosis and accelerated recovery from rat liver fibrosis. Gastroenterology , 2005;128:108-120
50. Li X, Meng Y, Wu P, Zhang Z, Yang X. Angiotensin II and Aldosterone stimulating NF-kappaB and AP-1 activation in hepatic fibrosis of rat. Regul Pept, 2007 ;138:15-25
51. Lee KS, Lee SJ, Park HJ, Chung JP, Han KH, Chon CY, Lee SI, Moon YM. Oxidative stress effect on the activation of hepatic stellate cells. Yonsei Med J, 2001 ;42:1-8
52. Lee KS, Buck M, Houglum K, Chojkier M. Activation of hepatic stellate cells by TGF alpha and collagen type I is mediated by oxidative stress through c-myb expression. J Clin Invest, 1995 ; 96: 2461-2468
53. Chaisson ML, Brooling JT, Ladiges W, Tsai S, Fausto N. Hepatocyte-specific inhibition of NF-kappaB leads to apoptosis after TNF treatment, but not after partial hepatectomy. J Clin Invest, 2002 ;110:193-202
54. Lang A, Schoonhoven R, Tuvia S, Brenner DA, Rippe RA. Nuclear factor kappaB in proliferation, activation, and apoptosis in rat hepatic stellate cells. J Hepatol, 2000 ;33: 49-58
55. Elsharkawy AM, Wright MC, Hay RT, Arthur MJ, Hughes T, Bahr MJ, Degitz K, Mann DA. Persistent activation of nuclear factor-kappaB in cultured rat hepatic stellate cells involves the induction of potentially novel Rel-like factors and prolonged changes in the expression of IkappaB family proteins. Hepatology, 1999 ; 30: 761-769
56. Anan A, Baskin-Bey ES, Bronk SF, Werneburg NW, Shah VH, Gores GJ.Proteasome inhibition induces hepatic stellate cell apoptosis. Hepatology, 2006 ;43:335-344
57. Racanelli V, Rehermann B. The liver as an immunological organ. Hepatology ,2006; 43: S54-S62
58. Fox ES, Cantrell CH, Leingang KA. Inhibition of the Kupffer cell inflammatory response by acute ethanol: NF-kappa B activation and subsequent cytokine production. Biochem Biophys Res Commun, 1996 ;225:134-140
59. Cao Q, Mak KM, Lieber CS. Dilinoleoylphosphatidylcholine decreases acetaldehyde-induced TNF-alpha generation in Kupffer cells of ethanol-fed rats. Biochem Biophys Res Commun, 2002 ;299:459-464
60. Shimohashi N, Nakamuta M, Uchimura K, Sugimoto R, Iwamoto H, Enjoji M, Nawata H. Selenoorganic compound, ebselen, inhibits nitric oxide and tumor necrosis factor-alpha production by the modulation of jun-N-terminal kinase and the NF-kappaB signaling pathway in rat Kupffer cells. J Cell Biochem, 2000 ;78:595-606
61. She H, Xiong S, Lin M, Zandi E, Giulivi C, Tsukamoto H. Iron activates NF-kappaB in Kupffer cells. Am J Physiol Gastrointest Liver Physiol., 2002 ; 283: G719-726
62. Anselmi K, Stolz DB, Nalesnik M, Watkins SC, Kamath R, Gandhi CR. Gliotoxin causes apoptosis and necrosis of rat Kupffer cells in vitro and in vivo in the absence of oxidative stress: exacerbation by caspase and serine protease inhibition. J Hepatol, 2007 ;47:103-113
63. Cressman DE, Greenbaum LE, Haber BA, Taub R. Rapid activation of post-hepatectomy factor/nuclear factor kappa B in hepatocytes, a primary response in the regenerating liver. J Biol Chem, 1994 ;269:30429-30435
64. Beraza N, Lüdde T, Assmus U, Roskams T, Vander Borght S, Trautwein C.Hepatocyte-specific IKK/NEMO expression determines the degree of liver injury.Gastroenterology, 2007, 132∶2 504– 2517
65. Geisler F, Algul H, Paxian S, Schmid R.M. Genetic inactivation of RelA / P65 sensitizes adult mouse hepatocytes to TNF - induced apoptosis in vivo and in vitro. Gastroenterology, 2007; 132∶2 489– 2503
66. Beg AA,Sha WC,Bronson RT,Ghosh S,Baltimore D. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature, 1995; 376: 167-170
67. Gallagher NJ, Young LS. Nuclear factor kappaB in liver disease. Gut,1999 ; 45:170-171
68. Kang KH, Lee KH, Kim MY, Choi KH. Caspase-3-mediated cleavage of the NF-kappa B subunit p65 at the NH2 terminus potentiates naphthoquinone analog-induced apoptosis. J Biol Chem. 2001 ;276:24638-24644
69. KarinM, Greten FR. NF - kappaB: linking inflammation and immunity to cancer development and progression . Nat Rew Immunol, 2005; 5∶749-759
70. Demoule A, Divangahi M, Yahiaoui L, Danialou G, Gvozdic D, Labbe K, Bao W, Petrof BJ. Endotoxin triggers nuclear factor-kappaB-dependent up-regulation of multiple proinflammatory genes in the diaphragm. Am J Respir Crit Care Med ,2006 ;174: 646-653
71. Liu SQ, Yu JP, Chen HL, Luo HS, Chen SM, Yu HG.. Therapeutic effects and molecular mechanisms of Ginkgo biloba extract on liver fibrosis in rats. Am J Chin Med, 2006;34:99-114
72. Lv P, Luo HS, Zhou XP, Chireyath Paul S, Xiao YJ, Si XM, Liu SQ. Thalidomide prevents rat liver cirrhosis via inhibition of oxidative stress. Pathol Res Pract, 2006;202:777-788
73. Lv P, Luo HS, Zhou XP, Xiao YJ, Paul SC, Si XM, Zhou YH. Reversal effect of thalidomide on established hepatic cirrhosis in rats via inhibition of nuclear factor-kappaB/inhibitor of nuclear factor-kappaB pathway. Arch Med Res,2007 ;38:15-27
74. Nanji AA, Jokelainen K, Rahemtulla A, Miao L, Fogt F, Matsumoto H, Tahan SR, Su GL. Activation of nuclear factor kappa B and cytokine imbalance inexperimental alcoholic liver disease in the rat. Hepatology, 1999;30:934-943
75. Nanji AA, Jokelainen K, Tipoe GL, Rahemtulla A, Dannenberg AJ. Dietary saturated fatty acids reverse inflammatory and fibrotic changes in rat liver despite continued ethanol administration. J Pharmacol Exp Ther, 2001;299:638-644
76. Nanji AA, Jokelainen K, Lau GK, Rahemtulla A, Tipoe GL, Polavarapu R, Lalani EN. Arginine reverses ethanol-induced inflammatory and fibrotic changes in liver despite continued ethanol administration. J Pharmacol Exp Ther, 2001;299:832-839
77. Ribeiro PS, Cortez-Pinto H, SoláS, Castro RE, Ramalho RM, Baptista A, Moura MC, Camilo ME, Rodrigues CM. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol, 2004 ;99:1708-1717
78. Zhong Z, Froh M, Connor HD, Li X, Conzelmann LO, Mason RP, Lemasters JJ, Thurman RG.. Prevention of hepatic ischemia-reperfusion injury by green tea extract. Am J Physiol Gastrointest Liver Physiol , 2002 ,283 :G957-G964
79. Okaya T, Lentsch AB. Hepatic expression of S32A/S36A I-κBαdoes not reduce postischemic liver injury. J Surg Res , 2005 ;124 :244-249
80. Luedde T, Assmus U, Wüstefeld T, Meyer zu Vilsendorf A, Roskams T, Schmidt-Supprian M, Rajewsky K, Brenner DA, Manns MP, Pasparakis M, Trautwein C. Deletion of IKK2 in hepatocytes does not sensitize these cells to TNF-induced apoptosis but protects from ischemia/reperfusion injury. J Clin Invest, 2005 ;115: 849-859
81. Xu J, Xie J, Bao M, Li Z, Yang Z. NF-kappaB/I-kappaB pathway during ischemia reperfusion injury of rat liver. Chin Med J (Engl),2003 ;116:1146-1149
82. Nüssler NC, Müller AR, Weidenbach H, Vergopoulos A, Platz KP, Volk HD,Neuhaus P, Nussler AK. IL-10 increases tissue injury after selective intestinal ischemia/reperfusion. Ann Surg ,2003 ,238 :49-58
83.徐钧,解军,鲍民生,李正中,杨镇.核转录因子-кB在FK506保护肝脏缺血再灌注损伤中的作用.中华实验外科杂志, 2003; 20: 232-233
84. Videla LA, Tapia G, Rodrigo R, Pettinelli P, Haim D, Santiba?ez C, Araya AV, Smok G, Csendes A, Gutierrez L, Rojas J, Castillo J, Korn O, Maluenda F, Díaz JC, Rencoret G, Poniachik J. Liver NF-kappaB and AP-1 DNA binding in obese patients. Obesity (Silver Spring) ,2009 ; 17: 973-979
85.陈芝芸,严茂祥,何蓓晖,刘庆生,孙丽伟.核转录因子кB在非酒精性脂肪肝大鼠肝组织中的表达.医学研究通讯, 2005;34:9-11
86.张爱忠,张赤志,许汉林,王汉敏.杞蓟制剂对非酒精性脂肪性肝炎大鼠肝组织核转录因子-κB / IκB的影响.实用肝脏病杂志, 2007; 10: 226-228
87. Guillermet-Guibert J, Saint-Laurent N, Davenne L, Rochaix P, Cuvillier O, Culler MD, Pradayrol L, Buscail L, Susini C, Bousquet C. Novel synergistic mechanism for sst2 somatostatin and TNFalpha receptors to induce apoptosis: crosstalk between NF-kappaB and JNK pathways. Cell Death Differ,2007 ;14: 197-208
88. Hagemann T, Wilson J, Kulbe H, Li NF, Leinster DA, Charles K, Klemm F, Pukrop T, Binder C, Balkwill FR. Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol, 2005 ;175:1197-1205
89. Bernal-Mizrachi L, Lovly CM, Ratner L. The role of NF-{kappa}B-1 and NF-{kappa}B-2-mediated resistance to apoptosis in lymphomas. Proc Natl Acad Sci U S A, 2006 ;103: 9220-9225
90. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature, 2006 ;441(7092):431-436
91. Lee KW, Kim MS, Kang NJ, Kim DH, Surh YJ, Lee HJ, Moon A. H-Ras selectively up-regulates MMP-9 and COX-2 through activation of ERK1/2 and NF-kappaB: an implication for invasive phenotype in rat liver epithelial cells. Int JCancer , 2006 ;119:1767-1775
92. Wang W, Luo HS, Yu BP. Exp ression of NF - kappaB and human telomerase reverse transcriptase in gastric cancer and precancerous lesions . World J Gastroenterol, 2004; 10 : 177 -181
93. Suh J, Rabson AB. NF-kappaB activation in human prostate cancer: important mediator or epiphenomenon? J Cell Biochem., 2004 ;9: 100-117
94. Qiao L, Zhang H, Yu J, Francisco R, Dent P, Ebert MP, R?cken C, Farrell G.. Constitutive activation of NF-kappaB in human hepatocellular carcinoma: evidence of a cytoprotective role. Hum Gene Ther, 2006 ;17: 280-290
95. Tai DI, Tsai SL, Chang YH, Huang SN, Chen TC, Chang KS, Liaw YF. Constitutive activation of nuclear factor kappaB in hepatocellular carcinoma. Cancer ,2000 ; 89: 2274-2281
96. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature, 2004 ; 431(7007): 461-466
97. Su XQ,Wu XH,Wu W. Kinetic alterations of liver nuclear factor-kappa B and TNF-αexpression at the early stage of HCC occurrence and clinical significances of their quantitative analysis . J Gastroenterol Hepatol,2006; 21(S2):A169
98. Wu JM, Sheng H, Saxena R, Skill NJ, Bhat-Nakshatri P, Yu M, Nakshatri H, Maluccio MA. NF-kappaB inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy. Cancer Lett, 2009 ; 278: 145-155
99. Sarkar FH,Li Y. NF-kappa B: A potential target for cancer chemoprevention and therap. Front Biosci, 2008; 13: 2950-2959
100.Elsharkawy AM, Mann DA. Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis. Hepatology , 2007 ; 46: 590-597
101.Thorgeirsson SS, Lee JS, Grisham JW. Functional genomics of hepatocellular carcinoma. Hepatology, 2006 ; 43(2 Suppl 1):S145-150
102.Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet, 2002 ; 31: 339-346
103.Lin A, Karin M. NF-kappaB in cancer: a marked target. Semin Cancer Biol. 2003 ; 13: 107-114.
104.Paur I, Austenaa LM, Blomhoff R. Extracts of dietary p lants are efficient modulators of nuclear factor kappa B . Food Chem Toxicol, 2008; 46 : 1288-1297